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2. Abstract 
 
Aberrant activation of the MAP kinase pathway is of fundamental importance 
for the transformation of numerous cell types. This can be achieved by 
oncogenic Ras and B-Raf missense mutations, which are common genetic 
lesions found in human cancers. Although a causal role of MAP kinase 
pathway hyperactivation in cancer development has been established, 
modulation of the pathway by the complex interplay of Ras and Raf proteins 
remains poorly understood. Here, I show that proto-oncogenic C-Raf 
antagonizes the oncogenic activity of the most frequent cancer-associated B-
Raf mutant, B-RafV600E, through the formation of B-RafV600E–C-Raf complexes 
with low kinase activity. B-Raf–C-Raf association is promoted by oncogenic 
Ras, providing a potential explanation for the exclusivity of oncogenic Ras 
mutations and B-RafV600E in human cancer. To study the suppressive function 
of C-Raf on B-RafV600E in vivo, a mouse model of B-RafV600E was developed. 
Activated murine B-RafV619E, analogous to human B-RafV600E, transforms 
MEFs and, when expressed in melanocytes, induces hyper-pigmentation in 
mice. As B-RafV619E expression results in a transformed phenotype in vitro 
and in vivo, this mouse model will be useful to further evaluate the relationship 
between C-Raf and B-RafV600E. As C-Raf has adverse effects on B-RafV600E-
induced transformation, its role in mediating transformation by oncogenic K-
RasG12D was examined. Homozygous loss of C-Raf impairs K-RasG12D-
mediated lung tumor initiation and cell survival in MEFs. In contrast, B-Raf is 
required for the proliferative advantage conferred by K-RasG12D in vitro and in 
vivo. Together, I demonstrate that Raf proteins can have cancer promoting as 
well as preventing roles depending on the oncogenic context.
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Die abnormale Aktivierung des MAP Kinasen Signalweges ist von 
grundlegender Bedeutung für die Transformation zahlreicher Zelltypen. Dies 
kann durch häufig in menschlichen Tumoren vorkommenden Ras und B-Raf 
Punktmutationen erreicht werden. Obwohl die kausale Rolle des hyperaktiven 
MAPK Signalweges in der Krebsenstehung etabliert ist, ist die Regulierung 
des Signalweges durch das komplexe Zusammenspiel von Ras und Raf 
Proteinen nur teilweise bekannt. In dieser Arbeit zeige ich, daß das Proto-
onkogen C-Raf der onkogenen Aktivität der am häufigsten im Krebs 
vorkommenden B-Raf Mutante (B-RafV600E) entgegenwirkt, indem es einen B-
RafV600E–C-Raf Komplex mit verminderter Kinaseaktivität bildet. 
Interessanterweise werden B-RafV600E–C-Raf Komplexe von onkogenem Ras 
stabilisiert, was das Fehlen von gemeinsam auftretenden Ras und B-Raf 
Mutationen in humanem Krebs erklären könnte. Um den hemmenden Einfluß 
von C-Raf auf B-RafV600E in vivo untersuchen zu können, wurde ein B-RafV619E 
Mausmodell entwickelt (murines B-RafV619E entspricht dem humanen B-
RafV600E). B-RafV619E transformiert von diesen Mäusen gewonnene MEFs und 
induziert Überpigmentierung wenn B-RafV619E in den Melanozyten dieser 
Mäuse aktiviert wird. Da die Expression von B-RafV619E zur Zelltransformation 
in vitro und in vivo führt, kann dieses Mausmodell zur weiteren Aufklärung der 
B-RafV600E–C-Raf Beziehung herangezogen werden. Da C-Raf einen negative 
Effekt auf B-RafV600E ausübt, wurde untesucht, ob C-Raf in der K-RasG12D-
induzierten Zelltransformation eine Rolle spielt. Der homozygote Knock-out 
von C-Raf unterdrückt K-RasG12D-induzierte Lungenkrebsentstehung und die 
anti-apoptotische Funktion von K-RasG12D in MEFs. Im Gegensatz dazu 
reguliert K-RasG12D die Zellteilung von Lungenkrebszellen in vivo und MEFs in 
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vitro durch B-Raf. Zusammenfassend habe ich gezeigt, daß Raf Proteine 
sowohl den Krebs begünstigende als auch unterdrückende Rollen spielen 
können und daß dies von dem onkogenen Kontext abhängig ist. 
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3. Introduction 
 
3.1 The Ras/Raf/MEK/ERK pathway 
Normal cellular behavior is controlled by complex signaling networks that 
ensure that the proper response to intra- and extracellular cues is executed. 
Signaling through the Ras/Raf/MEK/ERK pathway (or mitogen-activated 
protein kinase (MAPK) pathway) is triggered by extracellular stimuli and 
regulates a variety of biological processes, such as proliferation, 
differentiation and cell death. Binding of mitogenic ligands to receptor tyrosine 
kinases (RTKs), such as the epidermal-growth-factor-receptor (EGFR), 
induces activation of RTKs through autophosphorylation. Phosphorylated 
receptors recruit the adaptor protein growth-factor-receptor-bound protein 2 
(GRB2) by binding to its SH2 domain. SH2 (Src homology 2) domains are 
protein domains capable of binding to phosphorylated tyrosine residues. 
GRB2 binds the guanine exchange factor (GEF) son-of-sevenless (SOS) 
through its SH3 domain (a domain capable of binding Proline-rich motifs), 
thereby locating SOS to the plasma membrane. Ras proteins are also 
localized to the plasma membrane as a result of post-translational 
modifications. The close proximity of SOS and Ras results in activation of the 
latter by promoting nucleotide exchange on Ras. Active Ras recruits Raf 
proteins to the plasma membrane where it binds them and promotes their 
activation. Subsequently, Raf phosphorylates MAPK and extracellular signal-
regulated kinase (ERK) kinase 1 and 2 (MEK1 and MEK2), which in turn 
activate ERK1 and ERK2 by phosphorylation. Activated ERK has both 
cytoplasmic and nuclear effectors and most attention has been focused on its 
ability to phosphorylate transcription factors. Among the transcription factors 
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that are activated by ERK are the ETS family of transcription factors and AP1. 
As a consequence of engaging these transcription factors, key regulatory 
proteins of the cell cycle, such as the Cyclin D family, are expressed to 
promote cell cycle progression. This model of the pathway is widely accepted 
(for review see  Downward, 2003), however, it certainly is an 
oversimplification. There are additional mediators of the receptor-GRB2 
interaction. Furthermore, tyrosine phosphorylated non-receptor proteins can 
recruit GRB2 to the plasma membrane and additional enzymes can regulate 
the nucleotide exchange on Ras. Moreover, several proteins such as 14-3-3, 
kinase suppressor of Ras (KSR), and connector enhancer of KSR (CNK) are 
important regulators of the activation of the Raf/MEK/ERK cascade. Finally, 
negative regulators, some of which are regulated by the pathway itself, assure 
that the pathway is tightly controlled. Deregulation of the MAPK pathway is 
frequently observed in disease. Indeed, mutation of key components, such as 
Ras and B-Raf, results in hyperactivation of the pathway and commonly 
occurs in cancer. 
 
3.2 Ras proteins 
Ras research began in the 1960s when it was discovered that murine 
leukemia viruses prepared from a leukemic rat could induce sarcomas in 
newborn mice (Harvey, 1964). Several other retroviruses with similar tumor 
inducing potential were subsequently identified (Kirsten and Mayer, 1967; 
Peters et al., 1974; Rasheed et al., 1978). It was later established that these 
recombinant viruses had incorporated rat genes into their genomes (H-Ras in 
the Ha-MSV strain, K-Ras in the Ki-MSV strain) (Ellis et al., 1981). H-Ras and 
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K-Ras were discovered to be human oncogenes when genomic DNA isolated 
from human tumor cell lines was shown to transform NIH3T3 fibroblasts (Shih 
and Weinberg, 1982) and that these transformed cells contained genes 
homologous to the v-ras oncogenes (Der et al., 1982; Parada et al., 1982; 
Santos et al., 1982). Later, a third Ras gene, N-Ras, was discovered in 
human neuroblastoma and sarcoma cell lines (Hall et al., 1983; Reddy et al., 
1982). 
 
Figure 3.1: The Ras/Raf/MEK/ERK signaling pathway. See text for detailed 
description.
 
The Ras genes code for small GTPases and are ubiquitously expressed 
(Chesa et al., 1987; Furth et al., 1987; Leon et al., 1987). Interestingly, two 
alternative splice variants of K-Ras exist, K-Ras4A and K-Ras4B, which differ 
in their composition of the C-terminus. Ras proteins share a high degree of 
sequence homology (85%) and have comparable transforming and ERK-
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activating abilities, which led to the belief that Ras proteins are functionally 
redundant. However, gene targeting experiments revealed that Ras proteins 
have unique functions. H-Ras knock-out mice display no obvious phenotype 
(Esteban et al., 2001), indicating that H-Ras is dispensable for mouse 
development. A role for H-Ras in tumorigenesis has been established as H-
Ras deficiency impairs carcinogen-induced skin tumor formation (Ise et al., 
2000). Similar to H-Ras, N-Ras is not required for mouse development as N-
Ras null mice are viable (Esteban et al., 2001; Umanoff et al., 1995). N-Ras 
knock-out mice show a defective immune response and T-cell function (Perez 
de Castro et al., 2003). In contrast, K-Ras deficiency is embryonic lethal due 
to fetal liver defects and anemia (Johnson et al., 1997; Koera et al., 1997). 
However, this phenotype appears to be due to the lack of K-Ras4B 
expression, as K-Ras4A is dispensable for mouse development (Plowman et 
al., 2003). These results indicate that Ras proteins have non-overlapping 
functions and that K-Ras deficiency can not be compensated for by H-Ras 
and N-Ras. Furthermore, many human tumor types are associated with 
predominant mutations in one of the Ras genes, indicating that Ras proteins 
possess distinct oncogenic properties in different cell types. 
 
Ras proteins need to be localized to the plasma membrane in order to be 
activated (reviewed in Downward, 2003; Konstantinopoulos et al., 2007). 
Membrane anchoring is promoted by post-translational modification of the 
carboxy-terminal CAAX motif. Newly synthesized Ras is cytosolic and 
becomes isoprenylated on the Cysteine residue of its CAAX motif by 
Farnesyltransferase (FTase). This results in association of Ras with 
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intracellular membranes. Next, Ras converting enzyme 1 (RCE1) catalyzes 
the release of the three amino acids downstream of the isoprenylcysteine by 
endoproteolytic digest. Finally, the isoprenylcysteine is methylated by 
isoprenylcysteine carboxyl methyltransferase (ICMT) and translocated to the 
plasma membrane. Palmitoyltransferase adds one (N-Ras, K-Ras4A) or two 
(H-Ras) palmitoyl long-chain fatty acids to Cysteine residues just upstream of 
the farnesylated carboxy-terminal Cysteine, which stabilizes the interaction 
with the plasma membrane. K-Ras4B is not palmitoylated; instead, a lysine-
rich peptide in the C-terminus interacts with the negatively charged lipid head 
groups thereby enhancing the interaction with the plasma membrane. In the 
absence of FTase activity, K-Ras and N-Ras can by isoprenylated by 
geranylgeranyltransferase type I (GGTase-I), potentially explaining the 
disappointing performance of FTase inhibitors in an attempt to therapeutically 
target oncogenic Ras in cancer patients. 
  
Figure 3.2: Post-translational modification of Ras. See text for detailed 
description. F, 15-C farnesyl isoprenoid; GG, 20-C geranylgeranyl isoprenoid. 
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Once Ras is localized to the plasma membrane, it can be activated. Inactive 
Ras is bound to GDP and fails to interact with downstream effectors. 
However, guanine nucleotide exchange factors (GEFs), such as SOS 
catalyze the replacement of GDP with GTP, the most abundant guanine 
nucleotide in the cytoplasm. GTP-bound, active Ras can bind several effector 
substrates thereby activating about a dozen signaling pathways including the 
PI3K-AKT and Raf/MEK/ERK pathways. Ras has low intrinsic GTPase activity 
and slowly converts bound GTP to GDP. Importantly, GTP hydrolysis is 
greatly catalyzed by GTPase activating proteins (GAPs), resulting in 
inactivation of Ras. It is the balance of GEFs and GAPs that regulates the 
activation of wildtype Ras and its downstream signaling pathways.  
 
3.3 Raf proteins 
Like Ras oncogenes, C-Raf was discovered as an acquired oncogene in 
tumor-inducing retroviruses. The mouse type C virus 3611-MSV induced 
rapidly growing fibrosarcomas in mice and the oncogene that was cloned from 
it was termed v-raf while its cellular homologue was named C-Raf (Rapp et 
al., 1983). Shortly thereafter, the avian acute leukemia retrovirus MH2 was 
found to carry another potential oncogene in addition to v-myc (Jansen et al., 
1983a; Jansen et al., 1983b). Hybridization and sequencing analysis of the 
two viruses confirmed that they had in fact incorporated orthologic gene 
sequences of C-Raf (Jansen et al., 1984; Sutrave et al., 1984). Subsequently, 
two additional members of the Raf family were identified and termed A-Raf 
and B-Raf (Beck et al., 1987; Huebner et al., 1986; Huleihel et al., 1986; 
Ikawa et al., 1988; Sithanandam et al., 1990). 
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Raf proteins are Serine/Threonine kinases that share very high amino acid 
sequence homology in three conserved regions (CR1-3). CR1 contains the 
Ras-binding domain (RBD) and a Cysteine-rich domain (CRD), CR2 is 
thought to be the ‘hinge-region’ of the protein and contains regulatory Serine 
and Threonine residues, and CR3 spans the highly conserved kinase domain. 
Raf proteins are broadly expressed but vary in their expression levels. C-Raf 
is expressed at high levels in all tissues, whereas A-Raf and B-Raf are 
expressed highest in urogenital and neuronal tissues, respectively (Mercer 
and Pritchard, 2003 and references therein). Interestingly, B-Raf is subjected 
to alternative splicing which results in proteins that harbor a truncated N-
terminus or contain alternative exon 8b or 10a. Indeed, some B-Raf 
antibodies detect proteins between 60 and 96 kDa in size. Exons 8b and 10a 
localize to the hinge-region and are believed to change the conformation, 
thereby impacting on the kinase activity (Barnier et al., 1995; Papin et al., 
1998). 
 
All three Raf proteins possess kinase activity towards MEK but MAPK-
independent functions have only been described for C-Raf. In a kinase-
independent fashion, C-Raf antagonizes the pro-apoptotic proteins MST2 
(O'Neill et al., 2004), ASK1 (Chen et al., 2001) and BAD (Wang et al., 1996). 
Furthermore, C-Raf inhibits ROKα by direct interaction, thereby regulating cell 
death and migration (Ehrenreiter et al., 2005; Piazzolla et al., 2005). Whether 
A-Raf or B-Raf phosphorylate substrates other than MEK1/2, and have 
kinase-independent functions remains to be determined. 
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Upon Ras activation, Raf proteins are recruited to the plasma membrane. Ras 
binds to the RBD and with lower affinity to the Cysteine-rich domain located in 
CR1 (reviewed in Mercer and Pritchard, 2003). All Ras isoforms are able to 
bind to C-Raf but with varying intensities. K-Ras binds more efficiently than N-
Ras, which binds better than H-Ras (Voice et al., 1999). Less is known about 
the interaction of B-Raf or A-Raf with Ras, but B-Raf appears to bind H-Ras in 
vitro as efficiently as C-Raf (Okada et al., 1999; Shinkai et al., 1996). Ras-
binding itself is not sufficient to activate Raf but rather serves to translocate 
Raf to the plasma membrane where it is activated by phosphorylation and 
dephosphorylation events. A model for C-Raf activation has been proposed 
recently (Dhillon et al., 2002; Wellbrock et al., 2004a). Cytoplasmic inactive C-
Raf is phosphorylated at Serines 43, 259 and 621 by the cAMP-dependent 
kinase protein kinase A (PKA). S43 phosphorylation prevents the interaction 
of Ras with Raf through sterical hindrance, while phosphorylation of S259 and 
S621 promotes binding of 14-3-3 proteins and maintains C-Raf in an inactive 
conformation. S259 can also be phosphorylated by AKT. Ras-GTP displaces 
14-3-3 from C-Raf and, at the plasma membrane, S259 is dephosphorylated 
by phosphatases such as PP2A. Next, Serine 338 and Tyrosine 341 are 
phosphorylated by activating kinases, thereby negatively charging the N-
region, which is essential for full C-Raf activation. Src phosphorylates Y341 
(Mason et al., 1999; Wellbrock et al., 2004a); and the identity of the S338 
kinase may be PAK Serine/Threonine kinases (Wellbrock et al., 2004a). 
Finally, phosphorylation of T491 and S494 in the activation segment is 
required for C-Raf activation but the activating kinases remain elusive. The 
activation process of B-Raf is fundamentally different from that of C-Raf. In 
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contrast to C-Raf, B-Raf has two Aspartic Acid residues at the equivalent 
positions to Tyr340 and Tyr341 (Asp448 and Asp449). The negative charge of 
the Aspartic Acid residues is likely to mimic phosphorylation of these sites. 
Furthermore, Ser446 (equivalent to S338 in C-Raf) is constitutively 
phosphorylated. The presence of D448, D449 and pS446 allows inactive B-
Raf to adopt a fairly open conformation compared to C-Raf. Upon ligand 
binding B-Raf is recruited to the plasma membrane by Ras-GTP, where it is 
dephosphorylated at S365 (S259 in C-Raf), thereby releasing 14-3-3. 
Unknown kinase(s) then phosphorylate(s) B-Raf at Thr599 and Ser602, 
resulting in full activation of the kinase. The different mechanisms of activation 
may result in the frequent occurrence of activating mutations in B-Raf but not 
in C-Raf. Even though a model for A-Raf activation has not been proposed, A-
Raf activation is likely very similar to that of C-Raf based on their sequence 
similarities. This is supported by the notion that, similar to C-Raf, single amino 
acid substitution is not sufficient to activate A-Raf. Thus, all Raf proteins rely 
on phosphorylation of the activation segment within the kinase domain but 
differ in that A-Raf and C-Raf require additional phosphorylation within the N 
region of the kinase domain for full activity (Chong et al., 2001; Mason et al., 
1999; Zhang and Guan, 2000). 
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Figure 3.3: Schematic outline of Raf proteins. Conserved regions (CR) 1, 2, 
and 3 are depicted in yellow, orange, and red, respectively. The 
phosphorylation sites required for activation are highlighted. Note that S446 in 
B-Raf is constitutively phosphorylated (see text for detailed description). RBD, 
Ras binding domain; CRD, Cysteine-rich domain. 
 
Knock-out mouse models have provided further insight into the functions of 
Raf proteins. A-Raf knock-out mice survive embryonic development but die 
around weaning age due to postnatal neurological and gastrointestinal defects 
(Pritchard et al., 1996). Mice deficient for C-Raf die during embryonic 
development due to fetal liver apoptosis (Huser et al., 2001; Mikula et al., 
2001). Interestingly, neither A-Raf null nor C-Raf null cells exhibit defective 
MEK activation, suggesting that either B-Raf is the major activator of the 
MAPK pathway or that deficiency of one Raf protein is compensated for by 
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the other two (Huser et al., 2001; Mercer et al., 2002; Mikula et al., 2001; 
Zhong et al., 2007). Conditional deletion of C-Raf in cardiomyocytes leads to 
apoptosis and cardiac dysfunction, which is rescued by ASK1 ablation 
(Yamaguchi et al., 2004) Furthermore, C-Raf is required for erythroid 
differentiation (Kolbus et al., 2002; Rubiolo et al., 2006). B-Raf knock-out mice 
die during midgestiation due to apoptosis of terminally differentiated 
endothelial cells and systemic vascular collapse (Wojnowski et al., 1997). A 
recent report showed that conditional deletion of B-Raf impaired placental 
vascularization, leading to embryonic lethality, whereas B-Raf expression in 
the embryo proper is dispensable for development (Galabova-Kovacs et al., 
2006). This discrepancy between the germline and conditional knock-out mice 
could potentially be due to expression of a truncated B-Raf protein in the 
germline knock-out mice. Conditional B-Raf knock-out mice further revealed 
that B-Raf is critical for the development of the central nervous system (Chen 
et al., 2006; Galabova-Kovacs et al., 2008; Zhong et al., 2007) as well as for 
tumor angiogenesis and progression in the RIP-Tag model of insulinomas 
(Sobczak et al., 2008). Importantly, cells derived from conditional B-Raf 
knock-out mice exhibit decreased activation of the MAPK pathway (Galabova-
Kovacs et al., 2008; Galabova-Kovacs et al., 2006; Sobczak et al., 2008; 
Zhong et al., 2007). Thus, Raf proteins have distinct functions during 
embryonic development and B-Raf seems to be the major activator of the 
MAPK pathway in several cell types and contexts. 
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3.4 Regulation of the MAPK pathway 
As the MAPK pathway controls a multitude of biological processes, the 
transduction of extracellular stimuli has to be tightly regulated and is often 
ligand, context- and cell type-dependent. The first level of regulation of the 
MAPK pathway is represented by Ras-mediated Raf activation. The four Ras 
proteins vary in their affinity for the Ras binding domains of the individual Raf 
proteins (Weber et al., 2000). Furthermore, Ras proteins localize to distinct 
microdomains in the plasma membrane, thereby exposing Raf proteins to 
different environments (Hancock, 2003). In addition, Raf proteins may be 
activated by several activating kinases in Ras–dependent and –independent 
manners. Moreover, RHEB has been suggested to reduce Raf activity and 
dimerization potential by antagonizing phosphorylation of the N-region 
(Karbowniczek et al., 2004; Karbowniczek et al., 2006). Another layer of 
regulation is added by scaffolding and adaptor proteins. Binding to 14-3-3 
proteins maintains Raf in an inactive conformation, and displacement of 14-3-
3 is mediated by dephosphorylation of 14-3-3 binding residues on Raf. 
Moreover, kinase suppressor of Ras (KSR) mediates complex formation of 
Raf, MEK, and ERK, thereby promoting MAPK activation (Kolch, 2005). 
Another adaptor protein, connector enhancer of KSR (CNK), associates with 
Raf and co-operates with Ras to stimulate Raf activation (Kolch, 2005). 
Finally, Raf kinase inhibitor protein (RKIP) binds both Raf and MEK to prevent 
their physical interaction, thereby inhibiting MEK activation (Kolch, 2005). The 
biological outcomes also depend on signal intensity. Raf proteins form both 
homo- and heterodimers (Farrar et al., 1996; Luo et al., 1996; Weber et al., 
2001), and these complexes exhibit distinct activities towards MEK (Garnett et 
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al., 2005; Rushworth et al., 2006, Karreth et al., in press). Inactivation of the 
MAPK pathway is regulated by several mechanisms. First, SOS is 
phosphorylated by active ERK and p90 RSK-2, a MAPK target, leading to 
dissociation of GRB2 and down-regulation of the MAPK pathway (Dong et al., 
1996; Douville and Downward, 1997; Waters et al., 1995). Furthermore, ERK 
directly phosphorylates C-Raf to disrupt the interaction with Ras, thereby 
desensitizing C-Raf for additional stimuli (Dougherty et al., 2005). Second, 
MAPK signaling transcriptionally up-regulates the negative regulators Sprouty 
and Sprouty-related proteins with an EVH1 domain (SPRED). These proteins 
can bind and sequester both GRB2 and Raf, thereby antagonizing activation 
of the MAPK pathway (Kim and Bar-Sagi, 2004). Finally, the MAPK pathway 
is subjected to regulation by phosphates, such as dual-specificity 
phosphatases (DUSP) on several levels (Dhillon et al., 2007). 
 
3.5 Ras and cancer 
Ras is one of the most commonly mutated oncogenes in cancer. In fact, 
approximately 30% of cancer cases harbor a Ras mutation (Bos, 1989). Three 
hotspot residues have been identified – G12, G13, Q61 – but other, less 
common cancer-associated mutations with transforming ability have been 
found (for example Scholl et al., 2009). Mechanistically, the hotspot mutations 
impair the intrinsic GTPase activity of Ras and prevent the association with 
extrinsic GAPs, thereby locking it in the GTP-bound state. Thus, all Ras 
effector pathways are constitutively and growth-factor-independently 
activated. K-Ras is mutated in about 85% of cancers with Ras mutations and 
the K-Ras4A splice form has been shown to have higher oncogenic potential 
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than K-Ras4B (To et al., 2008; Voice et al., 1999). N-Ras and H-Ras 
mutations are relatively rare and found in 15% and <1% of cases. 
Interestingly, each Ras family member is mutated in a specific subset of 
human malignancies: K-Ras is commonly mutated in epithelial cancers of the 
pancreas, lung and colon; N-Ras mutations occur frequently in melanoma, 
liver and myeloid malignancies; and H-Ras mutations have been observed in 
bladder cancer. Intriguingly, the occurrence of Ras mutations in certain cell 
types appears to be dependent on the genomic locus rather than the gene 
itself (To et al., 2008). Furthermore, the wildtype K-Ras allele can act as a 
tumor suppressor in lung tumorigenesis driven by carcinogen-induced K-Ras 
mutations (Zhang et al., 2001), suggesting that Ras-mediated carcinogenesis 
is subject to multiple forms of modulation. 
 
3.6 Raf and cancer 
Despite being first identified as a viral oncogene, C-Raf is very rarely mutated 
in human cancer. In fact, only two germ-line C-Raf polymorphisms have been 
found in patients with therapy-related AML. Both of these mutations possess 
transforming properties but only one showed increased kinase activity 
(Zebisch et al., 2006). Furthermore, sequencing of 545 tumor cell lines 
identified four C-Raf mutations, three of which displayed no appreciable 
increase in kinase and transforming activity (Emuss et al., 2005). The 
remaining mutation showed increased kinase activity but failed to transform 
NIH3T3 fibroblasts (Emuss et al., 2005). These data suggest that C-Raf is not 
a target of somatic mutation in cancer, as single amino acid substitutions fail 
to hyperactivate C-Raf. This is likely due to the complex activation of C-Raf, 
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which cannot be mimicked by a single mutation. Similar to C-Raf, cancer-
associated mutations in A-Raf are extremely infrequent. One study found a 
single A-Raf mutation in 60 cell lines and 323 primary tissue samples but did 
not report on its transforming ability (Lee et al., 2005). B-Raf is the member of 
the Raf family that is frequently mutated in cancer. 8% of human tumors 
harbor a B-Raf mutation and cancers commonly associated with B-Raf 
mutations are melanoma, thyroid, ovarian and intestinal cancers. Cell types 
commonly harboring B-Raf and Ras mutations partially overlap, suggesting 
that these cell types are particularly susceptible to MAPK hyperactivation. 
Over 30 B-Raf mutations have been observed, all of which are in the kinase 
domain. There are two hotspots for B-Raf mutations, the DFG motif and the P 
loop, which interact to maintain B-Raf in the inactive conformation (Wan et al., 
2004). Mutations located in these motifs disrupt their interaction and promote 
the active conformation of B-Raf. Two distinct classes of B-Raf mutations 
have been identified. The more prominent class of mutations constitutively 
activates B-Raf, leading to increased activity towards MEK. The Glutamic Acid 
to Valine amino acid substitution at position 600 is the predominant B-Raf 
mutation and is found in over 85% of B-Raf mutant tumors. Val600 is flanked 
by activating phospho-residues Thr599 and Ser602 and replacing Val600 with 
a Glutamic Acid places a negative charge between Thr599 and Ser602, 
thereby mimicking phosphorylation of the two sites. The second class of 
mutations impairs the catalytic activity of B-Raf. These mutations localize to 
the Glycine residues of the GXGXXG motif in the P loop of the kinase domain. 
Even though these mutants adopt an open conformation, they have very 
limited activity towards MEK because they cannot optimally catalyze ATP. 
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However, impaired activity mutants are able to associate and co-operate with 
C-Raf to hyperactive the MAPK pathway (Garnett et al., 2005; Wan et al., 
2004). Interestingly, impaired activity mutations and increased activity 
mutations predominate in distinct cancer types, indicating that their 
transforming potential is cell type dependent and that additional factors are 
important for their full oncogenic activity. 
 
3.7 Modelling oncogenic Ras/Raf signalling in the mouse 
Karreth FA and Tuveson DA, Curr Opin Genet Dev. 2009;19(1):4-11  
 
 22
Available online at www.sciencedirect.com
Modelling oncogenic Ras/Raf signalling in the mouse
Florian A Karreth1,2 and David A Tuveson1The Ras/Raf/MEK/ERK (or MAPK) signalling pathway relays
extracellular stimuli to the nucleus, thereby regulating diverse
cellular responses such as proliferation, growth, differentiation
and apoptosis. Perturbation of these processes by aberrant
MAPK signalling often leads to malignant transformation as
indicated by the frequent occurrence in human cancers of
genetic alterations affecting this pathway. In recent years,
genetically modified mouse models have proven instrumental
in unravelling how deregulated MAPK signalling leads to
disease. Indeed, conditional activation of oncogenic K-Ras or
B-Raf in mice resulted in neoplasms that closely resemble the
human disease. Such tractable mouse models will enable the
pursuit of basic biological mechanisms and translational
applications regarding the MAPK pathway.
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Introduction: the MAPK pathway
The MAPK pathway is essential for organismal devel-
opment and has been elucidated through genetic and
biochemical approaches over the past several decades.
The pathway is proximally activated by growth factor
binding to receptor tyrosine kinases (RTK), resulting in
RTK phosphorylation and activation. Consequently,
adaptor molecules localize to RTKs followed by recruit-
ment and activation of guanine nucleotide-exchange fac-
tors (GEFs). GEFs catalyse the transition from GDP-
bound, inactive Ras to GTP-bound, active Ras. Ras-GTP
interacts with more than a dozen effector molecules to
regulate a variety of biological processes [1]. GTPase-
activating proteins (GAPs) allosterically stimulate the
intrinsic GTPase activity of Ras, leading to GTP hydroly-
sis and Ras inactivation. To activate the MAPK signalling
cascade, Ras recruits Raf to the cell membrane, where Raf
is activated and subsequently forms complexes with
MEK, ERK and scaffolding proteins. Raf then phosphor-Current Opinion in Genetics & Development 2009, 19:4–11ylates MEK, which in turn phosphorylates ERK. ERK
both activates cytosolic substrates and translocates to the
nucleus to stimulate diverse gene expression programs
through transcription factors such as JUN and ELK1
(Figure 1). The recent recognition of inhibitory feedback
loops through phosphatases and binding proteins with no
obvious catalytic activity has added a new dimension to
our understanding of the MAPK pathway. Therefore, the
MAPK ‘pathway’ is rather a complex network that is still
being elucidated.
The importance of the MAPK pathway in neoplasms is
evident through the discovery of mutant alleles that
hyperactivate the pathway in a variety of human cancers.
First, oncogenic mutations in RTKs abnormally activate
Ras and its downstream substrates [2]. Second, activating
Ras mutations have been detected in approximately 30%
of human cancers [3]. These mutations occur in codons
12, 13, and 61 and markedly diminish GTPase activity,
thereby rendering Ras locked in the GTP-bound, active
state. In mammals, the Ras family consists of three genes:
K-Ras, N-Ras and H-Ras. While K-Ras is the predomi-
nantly mutated family member (in 85% of cancers
harboring Ras mutations), N-Ras and H-Ras mutations
are relatively uncommon (15% and <1%, respectively)
[4]. Interestingly, each Ras family member is mutated in a
specific subset of human malignancies: K-Ras is com-
monly mutated in epithelial cancers of the pancreas, lung
and colon; N-Ras mutations occur frequently in mela-
noma, liver and myeloid malignancies; and H-Ras
mutations have been observed in bladder cancer
(Table 1). Third, activating mutations in B-Raf , a mem-
ber of the Raf family, have been discovered with high
frequency in melanoma (in a non-overlapping pattern
with mutations in N-Ras) and, to a lesser extent, in
thyroid, ovarian and colon cancer [5–7]. Importantly,
activating missense mutations do not occur in the other
members of the Raf family, A-Raf and Raf-1, which may
be due to their more complex mode of activation [8].
Single amino acid substitutions are sufficient to promote
the active conformation of B-Raf, thereby constitutively
activating the MAPK pathway. Finally, loss of negative
regulators, such as members of the Sprouty family and
GAPs such as NF1, can indirectly hyperactivate the
MAPK signalling cascade. It is estimated that most
tumors exhibit deregulation of the MAPK pathway, mak-
ing it an attractive target for therapeutic intervention.
In recent years, several mouse models have been generated
to establish a causal relationship between MAPK
mutations found in human cancer and tumor development.
These mouse models have furthered our understanding ofwww.sciencedirect.com
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Figure 1
The Ras/Raf/MEK/ERK pathway. Binding of growth factors (GF) to receptor tyrosine kinases (RTK) leads to recruitment of adaptor proteins and
guanine exchange factors (GEF). GEFs promote the active form of Ras (RasGTP). Ras signals to different pathways, one being the Raf/MEK/ERK
pathway. Ras activates Raf, which may have several downstream effectors. Raf phosphorylates MEK followed by ERK phosphorylated by MEK. ERK
has cytoplasmic substrates and also translocates to the nucleus to activate a variety of transcriptional programmes through several transcription
factors (TFs). The signalling cascade is negatively regulated by Sprouty proteins (SPRY) and dual-specificity phosphatases (DUSP). Proteins in red
have been found genetically altered in human cancers resulting in hyperactivation of the MAPK pathway.cellular transformation by aberrant MAPK signalling and
offer a powerful tool for preclinical testing of novel thera-
peutics. In this review, we will discuss the most recent
advances of mouse cancer models that involve deregulated
MAPK pathway activation.
Oncogenic Ras mouse models
Mouse models of cancer are most valuable when they
recapitulate the cardinal pathophysiological and molecu-
lar aspects of the corresponding human malignancy [9].
For example, accurate mouse models of neoplasias that
utilize the conditional endogenous expression of onco-www.sciencedirect.comgenic K-Ras have been described [10–12]. These models
incorporated a loxP-flanked transcriptional stop cassette
(lox-stop-lox or LSL) to conditionally permit spatiotem-
poral regulation of oncogenic K-Ras expression by Cre-
mediated excision of the LSL. This approach allows
oncogenic K-Ras expression at physiological levels; how-
ever, a potential weakness is the expression of only one
copy of wildtype K-Ras in cells lacking Cre. Even though
the models by Guerra et al. [10] and Jacks and colleagues
[11–13] differed in their neoplastic phenotypes, in each
model expression of oncogenic K-Ras was sufficient to
induce hyperplasia. While the Jacks laboratory describedCurrent Opinion in Genetics & Development 2009, 19:4–11
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Table 1
Occurrence of Ras and B-Raf in human cancers.
Tissue K-Ras
(%)
N-Ras
(%)
H-Ras
(%)
BRAF
(%)
Biliary tract 32 1 0 14
Bone 1 0 2 0
Breast 5 1 1 2
CNS 1 2 0 3
Cervix 8 1 9 1
Endometrium 14 0 1 1
GI tract (site indeterminate) 19 0 0 0
Haematopoietic and
Lymphoid tissue
5 12 0 2
Kidney 1 0 0 0
Large intestine 32 3 0 13
Liver 7 4 0 3
Lung 17 1 0 2
Melanoma 1 17 1 64
Oesophagus 4 0 0 2
Ovary 15 4 0 13
Pancreas 60 2 0 2
Prostate 8 1 6 6
Salivary gland 4 0 16 0
Skina 2 19 5 41
Small intestine 20 25 0 5
Soft tissue 12 6 7 3
Stomach 6 2 4 1
Testis 5 4 0 0
Thyroid 3 7 4 37
Urinary tract 4 3 12 0
Data derived from COSMIC database; http://www.sanger.ac.uk/
genetics/CGP/cosmic.
a Skin cancers including melanoma.pulmonary [12], pancreatic [13] and colonic [11] hyperpla-
sia and neoplasms, Guerra et al. reported lung adenomas,
histiocytic sarcomas and sarcomas [10]. Further pheno-
types have been characterized in both models and will
be discussed in more detail below. The phenotypic differ-
ences may be attributed to the genetic backgrounds of the
mouse strains used, the amino acid substitution modelled
(G12V vs. G12D in ref. [10] vs. refs. [11–13], respectively),
or the use of a bicistronic K-RasG12V-IRES-bgeo mRNA that
could influence transcription and/or translation [10]. Using
an inducible transgenic approach, it has been shown in vivo
that variations in mutant Ras levels manifested different
biological outcomes [14]. Indeed, high levels of mutant
H-RasG12V induced a growth arrest in mammary epithelial
cells in a p16INK4A/p19ARF- and p53-dependent manner,
whereas expression levels similar to endogenously
expressed K-RasG12D resulted in mammary epithelial
hyperplasia but were insufficient to induce frank malig-
nancy [14]. Although Ras mutations are uncommon in
human breast cancer, these findings further substantiate
the notion that initial expression of mutant Ras genes at
physiological levels is required to accurately study Ras-
induced human cancers in mice. Because mutations in K-
Ras are common in many human tumor types, the de-
velopment of mice expressing physiological levels of onco-
genic K-Ras thus provided the opportunity to study a
variety of human cancers in mice.Current Opinion in Genetics & Development 2009, 19:4–11To this end, K-Ras mutant mice have been crossed to
several tissue-specific Cre transgenic mouse strains.
These mouse models displayed hyperplastic and neoplas-
tic phenotypes in epithelial, mesenchymal and haemato-
poietic cells. When crossed to pancreas-specific Cre
strains, LSL-K-RasG12D mice developed a preinvasive
neoplasm of pancreatic ductal adenocarcinoma (PDA),
termed pancreatic intraepithelial neoplasia (PanIN),
which spontaneously progressed to metastatic PDA at a
low frequency [13]. Furthermore, oncogenic K-Ras
cooperated with p16INK4a/p19ARF deficiency [15], p53
mutation [16], perturbed TGFb signalling [17–19],
TGFa activation [20] and chronic pancreatitis [21] to
accelerate the formation of PanIN and metastatic cancer.
Interestingly, LSL-KrasG12D mice deficient in TGFb
signalling also developed intraductal papillary mucinous
neoplasms (IPMN) [17] and mucinous cystic neoplasms
(MCN) [19], which are additional preinvasive precursor
lesions of PDA, suggesting that more than one route to
pancreatic ductal adenocarcinoma may exist. It is cur-
rently unclear which pancreas cell type initiates PanIN in
response to oncogenic K-Ras. Some reports point to the
exocrine compartment [21–23]; however, it remains
incompletely understood whether progenitor cells or
terminally differentiated ductal or acinar cells give rise
to PanIN and PDA. These pancreatic cancer models
closely recapitulate the initiation and progression of the
human disease and will allow further characterization of
pancreatic cancer development.
In addition to pancreatic cancer, lung cancer can also be
modelled with oncogenic K-Ras mice. Intranasal ade-
noviral Cre (Ad-Cre) instillation in LSL-K-RasG12D
mice led to atypical adenomatous hyperplasia, epithelial
hyperplasia and adenomas that spontaneously pro-
gressed to pulmonary adenocarcinoma [12]. Bronchioal-
veolar stem cells (BASCs) have been identified in the
bronchioalveolar duct junction of mouse lungs [24].
Importantly, BASCs expanded in response to oncogenic
K-Ras expression in early lung tumors [24], suggesting
that transformed lung stem cells may possess cancer-
initiating properties. Furthermore, cooperation of K-
RasG12D with both loss and mutation of p53 as well
as with PTEN deficiency was demonstrated [25,26].
Interestingly, MAPK activation was not seen in pre-
cursor lesions but could be detected in later stage
lesions in K-RasG12D mice lacking functional p53
[12,26]. These studies suggest that oncogenic K-Ras-
induced MAPK pathway activation remains low,
possibly through negative feedback loops. However,
in precursor lesions loss of p53 function permits the
acquisition of additional mutations that attenuate those
feedback loops, leading to elevated MAPK pathway
signalling and overt malignancy. This model will prove
useful for determining the role of oncogenic K-Ras in
lung cancer as well as effector pathways relevant for
therapeutic treatment.www.sciencedirect.com
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not an initiating event in colon cancer [27]. Expression of
K-RasG12V-IRES-bgeo alone was not sufficient to induce
colonic hyperplasia; however, cooperation with loss of
Apc was observed [28]. In other studies, activation of
K-RasG12D in colonic epithelium promoted hyperproli-
feration [11,29,30], which could be rescued by pharma-
cological MEK inhibition, thus demonstrating
dependence of hyperplasias on the MAPK pathway
[30]. Furthermore, K-RasG12D expression accelerated
colon cancer progression induced by Apc deficiency
[30]. The discrepancies in the induction of hyperplasia
observed in the two models may be attributed to the
reasons discussed above. Nevertheless, both models
demonstrated promotion of colonic tumor progression
by oncogenic K-Ras.
As opposed to pancreas, lung and colon cancer, K-Ras
mutations occur infrequently in the endometrium and
soft tissue. Interestingly, injection of Ad-Cre in the bursal
cavity of LSL-K-RasG12D mice induced endometriotic-
like lesions and peritoneal endometriosis [31]. In
addition, concomitant loss of PTEN led to endometrioid
ovarian adenocarcinoma, suggesting that K-RasG12D-
induced endometriosis may represent a precursor lesion
to ovarian adenocarcinoma [31]. K-RasG12D was also
reported to be oncogenic in mesenchymal cells, as intra-
muscular Ad-Cre injection in K-RasG12D mice lacking
either functional p53 or p16INK4A/p19ARF promoted the
formation of soft tissue sarcoma [32]. Thus, LSL-K-
RasG12D mice appear to recapitulate the full spectrum
of human malignancies carrying K-Ras mutations.
In contrast to solid tumors, K-Ras is not the predominant
Ras oncogene in haematopoietic malignancies. Never-
theless, expression of K-RasG12D in haematopoietic cells
caused a fatal myeloproliferative disease similar to human
juvenile myelomonocytic leukaemia and chronic myelo-
monocytic leukaemia [33,34] that never progressed to
acute myeloid leukaemia. By contrast, mice concomi-
tantly expressing oncogenic K-Ras and a PML-RARa
translocation transgene succumbed to a rapid onset,
highly penetrant acute promyelocytic leukaemia-like dis-
ease [35], suggesting cooperation of K-RasG12D and sec-
ondary mutations in leukaemogenesis. These K-Ras
mouse models provided experimental support to a model
in which mutation of K-Ras is the neoplasia-initiating
event and progression to malignant cancer requires
additional genetic changes such as inactivation of tumor
suppressor genes.
Compared to oncogenic K-Ras, studies on mutant N-Ras
and H-Ras function have largely remained limited in their
use of transgenic approaches. For instance, retroviral
infection of bone marrow cells with mutant N-Ras [36]
as well as H-Ras and K-Ras [37] alleles, followed by
transplantation into lethally irradiated hosts, revealedwww.sciencedirect.comthe leukemogenic potential of all Ras isoforms. In another
study, melanocyte-specific expression of H-RasG12V pro-
moted melanomagenesis, which was accelerated by
p16INK4a/p19ARF deficiency [38]. In addition, mice
expressing an H-RasG12V transgene in livers deficient
for b-catenin developed hepatocellular carcinomas [39].
Although these transgenic mouse models have contrib-
uted to the understanding of Ras-mediated tumorigen-
esis, they are limited by non-physiological expression
levels and the fact that H-RAS mutations are not found
in human leukaemia, melanoma or hepatocellular carci-
noma.
The successful development of conditional K-Ras mouse
models prompted the generation of mouse models carry-
ing cancer-associated mutations in the other Ras family
members. Mice conditionally expressing endogenous
mutant N-Ras were generated in a fashion similar to
LSL-K-RasG12D mice and crossed to colonic epithelia-
specific Cre mice. In contrast to K-RasG12D mice, colonic
expression of N-RasG12D neither induced hyperplasia nor
cooperated with loss of Apc to promote tumor progression
[30], providing a rationale for the absence of mutations in
colon cancer. The phenotypic differences could reflect
that the G12D mutation confers a weaker oncogenic
potential on N-Ras than on K-Ras or could reflect differ-
ent expression levels of the two oncogenes. Accordingly,
N-Ras Q61 mutations are more frequently found in
human cancers than G12 mutations (COSMIC database;
http://www.sanger.ac.uk/genetics/CGP/cosmic). Given
the lack of a neoplastic phenotype in the mouse colon
it will be of future interest to evaluate the oncogenic
potential of N-Ras in cell types that show frequent N-
RAS mutations in humans such as melanocytes and
haematopoietic cells.
H-RAS mutations are uncommon in spontaneous human
cancer. However, germline expression of mutant H-RAS
is associated with Costello syndrome (CS) and CS
patients display a certain predisposition to neuroblasto-
mas, rhabdomyosarcomas, and bladder carcinomas [1].
Mice expressing germline H-RasG12V phenocopied cer-
tain features of CS; however tumors were extremely rare
[40]. This phenotype suggests that H-Ras is a poor
initiating oncogene and may be mutationally activated
in spontaneous cancers only at later stages during tumor
development when cooperating genetic lesions have
already occurred. Alternatively, H-Ras could be a less
potent oncogene in mice compared to humans.
Oncogenic Raf mouse models
Following the identification of BRAF mutations in
human malignancies, novel mouse strains modelling
those mutations have been developed. Pritchard and
colleagues created a B-RafV600E mouse by employing a
strategy in which mice are heterozygous mutant for B-Raf
in cells expressing Cre and homozygous wildtype forCurrent Opinion in Genetics & Development 2009, 19:4–11
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status in human neoplasms as well as in surrounding
normal tissues [41]. B-RafV600E activation in a variety
of somatic tissues by Mx1-Cre caused death in all animals
within a month due to the development of nonlymphoid
leukaemia of the histiocytic type [41]. Interestingly,
human leukaemia has not been associated with BRAF
mutations thus far. This discrepancy may represent dis-
tinct susceptibility of haematopoietic cells to oncogenic
stimuli in humans and mice. A second study using a
similar mouse model reported lung adenoma formation
in B-RafV600E mice after intranasal Ad-Cre instillation
[42]. Even though adenomas developed with complete
penetrance, they rarely progressed to adenocarcinoma,
and rather demonstrated a senescence-like growth arrest
following hyperplasia [42]. Interestingly, no growth
arrest was observed in KrasG12D-induced lung adenomas,
which eventually progressed to malignancy [12],
suggesting that activation of other Ras effector pathways
may be required for tumor progression (or example see
ref. [57]). B-RafV600E could, however, cooperate with loss
of p53 or p16INK4A/p19Arf, known mediators of senescence,
to induce adenocarcinomas [42]. These studies provided
experimental evidence for murine tumor initiation by
mutation of B-Raf. It is expected that oncogenic B-Raf
mice will prove valuable for investigating B-Raf-mediated
transformation in a variety of other cancers such as mela-
noma, thyroid and colon cancer.
Further evidence for the oncogenic properties of B-Raf
was provided by a forward genetic screen employing
transposon-mediated mutagenesis. In a p19Arf-deficient
background, B-Raf was the most frequently disrupted
gene, leading to acceleration of sarcoma formation [43]. In
the majority of cases, the T2/Onc transposon integrated in
intron 9, in the orientation that directed expression of the
C-terminal B-Raf kinase domain [43]. Similarly, trans-
genic expression of the kinase domain of Raf-1 sufficed to
induce lung adenomas [44], and additional deletion of E-
cadherin led to metastatic progression [45]. Furthermore,
Raf-1 lacking the N-terminal negative regulatory domain
cooperated with Akt activation and p19Arf loss to promote
the formation of gliomas [46]. However, expression of
truncated forms of B-Raf or Raf-1 has not been associated
with sporadic human malignancies and activating
mutations in CRAF have not been found in cancer thus
far. Even though the preclinical potential of these models
may be limited for the above reasons, they have con-
firmed the importance of MAPK pathway activation in
tumor development.
Mouse models of regulators of the MAPK
pathway
The MAPK pathway is subjected to extensive regulation
by posttranslational processing enzymes, phosphatases
and negative feedback loops. Disruption of this regula-
tion leads to pathway hyperactivation that mimics acti-Current Opinion in Genetics & Development 2009, 19:4–11vating Ras mutations as has been demonstrated in mouse
models lacking the Ras GAP neurofibromin (NF1)
(reviewed in [47,48]). In addition to GAPs for Ras, other
proteins function to attenuate the MAPK pathway such as
the dual-specificity phosphatases (DUSPs) and Sprouty
(Spry) proteins. Spry proteins inhibit the MAPK pathway
by binding to Raf as well as to Grb2, an adaptor protein
important for the recruitment of Ras GEFs [49]. Expres-
sion of Spry-1, Spry-2, and Spry-4 was increased upon
K-RasG12D expression in the lung [50], indicating that
negative feedback loops are upregulated in response to
oncogenic K-Ras to compensate for augmented MAPK
signalling. Furthermore, Spry-2-deficiency increased the
size of K-RasG12D-induced lung tumors [50], suggesting
that negative feedback regulation has tumor suppressive
activity in the context of oncogenic K-Ras. Besides Spry
proteins, MAPK phosphatases represent another way of
negatively regulating the MAPK pathway through depho-
sphorylation of ERK1 and ERK2. Tyrosine, serine/threo-
nine as well as dual-specificity phosphatases that act on
ERK proteins have been identified and knockout mice
have been generated to several of these (reviewed in
[51]). However, the effect of phosphatase depletion on
oncogenic Ras and Raf signalling has not yet been deter-
mined.
In addition to regulation of its downstream signalling
effectors, Ras itself is regulated through post-translational
modification. To increase membrane affinity and promote
protein interaction, Ras is modified at the carboxy-terminal
CAAX motif. First, the cysteine residue is isoprenylated by
farnesyltransferase (FTase), followed by endoproteolytic
release by Ras converting enzyme 1 (RCE1) of the three
amino acids downstream of the isoprenylcysteine. Finally,
the isoprenylcysteine residue is carboxyl methylated by
isoprenylcysteine carboxyl methyltransferase (ICMT).
However, in the absence of FTase activity, K-Ras and
N-Ras can be isoprenylated by geranylgeranyltransferase
type 1 (GGTase-I), a phenomenon providing an expla-
nation for the disappointing performance of FTase inhibi-
tors in clinical trials. Accordingly, genetic ablation of
FNTB, the gene encoding FTase, in K-RasG12V-expressing
cells did not prevent lung tumorigenesis [52]. Surpris-
ingly, the K-RasG12D-induced myeloproliferative disease
was accelerated upon genetic deletion of RCE1 [53],
suggesting that RCE1 may have a poorly understood tumor
suppressor role in cells and that RCE1 is not required for
Ras oncogenesis. By contrast, the lack of either GGTase-I
or ICMT ameliorated the lung tumor and myeloprolifera-
tive disease-like phenotypes in K-RasG12D mutant mice
[54,55]. As K-Ras is still farnesylated in the setting of
GGTase-I ablation, other CAAX proteins that undergo
geranylgeranylation must also be required for K-
RasG12D-mediated transformation. These findings imply
that GGTase-I or ICMT may represent more suitable
targets than RCE1 for therapeutic intervention in Ras
associated malignancies, either alone or in combinationwww.sciencedirect.com
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modifying enzymes as therapeutic targets needs further
investigation.
Conclusions and future outlook
The development of preclinical mouse models has con-
firmed a causal role of oncogenic K-Ras expression in a
variety of tumor types. Oncogenic K-Ras expression can
initiate multiple malignancies, consistent with the
demonstration of K-Ras mutations in different types of
human preneoplasms. The cancer-initiating cell type
described by Kim et al. for pulmonary adenocarcinoma
[24] should now be pursued for other K-Ras-driven can-
cers.
The finding that N-Ras and H-Ras have weak oncogenic
abilities in mice was somewhat surprising and may not
reflect observations made in human malignancies. Alter-
natively and in contrast to K-Ras, N-Ras and H-Ras may
not be initiating oncogenes and may be mutated only at
later stages during tumor progression. Therefore, to dis-
tinguish between these two possibilities, the acceleration
of tumor progression by N-Ras or H-Ras in combination
with tumor suppressor deficiency needs to be investi-
gated.
Each Ras family member is associated with different
kinds of cancer. Moreover, mutant B-Raf-harbouring
cancers do not completely overlap with cancers carrying
Ras mutations (e.g. mutant B-Raf has not been detected
in myeloid malignancies where N-Ras is the most com-
monly mutated Ras gene; see Table 1), indicating that
activation of the MAPK pathway alone is unlikely to
promote cancer. In fact, it has been shown in mouse
models [56,57] and cell culture [58] that activation
of other Ras effector pathways is important for tumor-
igenesis. The ability of endogenously expressed, mutant
Ras to activate certain effector pathways may vary be-
tween the three family members and could be influenced
by factors such as subcellular localization of Ras and cell
type. Additionally, the oncogenic mutations may confer
different activity onto Ras and Raf, which may also
depend on cell type. Understanding the difference in
oncogenic activities between mutant K-Ras, N-Ras, H-
Ras and B-Raf as well as the cellular context in which they
are transforming should ultimately explain the tropism of
these oncogenes. Finally, the development of preclinical
mouse models of oncogenic Ras/Raf signalling will prove
instrumental for developing novel therapeutics in a
timely manner.
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4. Materials and Methods 
 
4.1 DNA manipulation 
Standard procedures were used for DNA manipulations. A detailed 
description can be found in ‘Current Protocols in Molecular Biology, Volume 
1’. In brief, restriction digests were set up the following way: 
1ul restriction enzyme (2-10 units, New England Biolabs) 
1ul 10x buffer (New England Biolabs) 
1ul 10x BSA (1ug/ul, New England Biolabs) 
0.1-0.5ug DNA 
H2O to a final volume of 10ul. 
Restriction digests were incubated at 37ºC for a minimum of an hour and 
separated on 1% TAE agarose gels. Gel extraction of DNA, Minipreps and 
Midipreps (QIAquick Gel Extraction Kit, QuickLyse Miniprep Kit, QIAfilter 
Midiprep Kit, respectively, all Qiagen) were performed according to the 
manufacturer’s instructions. Ligations were set up the following way: 
1ul Ligase (New England Biolabs) 
1ul Ligase buffer (New England Biolabs) 
Vector and Insert DNA at a ratio of 1:3 
H2O to a final volume of 10ul. 
Ligations were incubated at 16ºC over-night, precipitated by adding 1ul 
Glycogen, 40ul H2O and 500ul N-Butanol, centrifuged and the pellet air-dried. 
DNA was resuspended in 10ul of H2O and 2ul were electroporated into 
electrocompetent E.coli (DH10a, either home-made or from Invitrogen) using 
a BioRad Micropulser and plated onto LB agar plates containing either 
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Ampicillin or Kanamycin (prepared by the media kitchens of the AFCRI or 
CRI). Bacteria were grown over-night at 37ºC and colonies picked the next 
day for diagnostic analysis. 
 
4.2 Polymerase Chain Reaction (PCR) 
For PCR reactions either the PCR core kit (Roche) or Phusion Hot Start High-
Fidelity DNA Polymerase (New England Biolabs) were used following the 
manufacturer’s instructions. 0.25ul of each 100uM primer solution were used 
per 20ul reaction. PCR programs were as follows: 
1. initial denaturation: 96ºC, 2 minutes 
2. denaturation: 96ºC, 30 seconds 
3. annealing: 58-66ºC, 30 seconds 
4. extension: 72ºC, 1-3 minutes 
Repeat steps 2.-4. 34 times 
5. final extension: 72ºC, 5 minutes 
6. 4ºC, forever 
Annealing temperature was pre-determined by a gradient PCR reaction with 
annealing temperatures ranging from 55ºC to 68ºC. Extension temperatures 
were chosen depending on the size of the fragment to be amplified. PCR 
reactions were run on a BioRad DNA Engine Dyad Peltier Thermal Cycler 
(BioRad). 
 
4.3 Colony lift 
Nylon membranes were placed onto bacteria plates for 30 seconds followed 
by incubation on Whatman paper soaked with Denaturation solution (1.5M 
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NaCl, 0.5M NaOH), then Neutralization solution (1.5M NaCl, 0.5M Tris-HCl 
pH7.5) and finally 3xSSC for 5 minutes each. Membranes were air dried and 
DNA cross-linked by 240uJ/cm2 UVC irradiation. Pre-hybridization, 
hybridization with radio-labeled probe and exposure to film was performed as 
for Southern blotting (see below). 
 
4.4 Plasmids 
B-Raf was PCR amplified from mouse cDNA, a flag-tag or HA-tag introduced 
at the C-terminus and cloned into pBabe-puro or pWZL-hygro, respectively. 
The N-terminus of B-Raf was amplified using the following primers: braf-
BamHI-fwd 5’-ccggatcccagtgtggtggtacgtaggaattggaagcatggcggcgctgagtggc-3’ 
(BamHI restriction site is underlined) and braf-ClaI-rev 5’-
ggaattttccatcgatattcacagg-3’ (ClaI restriction site is underlined). The C-
terminus of B-Raf was amplified using the following primers: braf-ClaI-fwd 5’-
cctgtgaatatcgatggaaaattcc-3’ (ClaI restriction site is underlined) and braf-flag-
SalI-rev 5’-gggtcgaccactgtgctggcgaattgtcaCTTATCGTCGTCGTCATCCTTGT 
Aatcgtggactggaaacc-3’ (SalI restriction site is underlined and flag tag is 
depicted by capital letters) or braf-HA-SalI-rev 5’-gggtcgaccactgtgctggcgaattg 
tcaTATCCGTATGATGTGCCGGATTATGCAatcgtggactggaaacc-3’ (SalI 
restriction site is underlined and HA tag is depicted by capital letters). The B-
Raf N-terminal and C-terminal fragments were digested with BamHI and ClaI 
(partial digest as there is another BamHI site in the B-Raf cDNA) or ClaI and 
SalI, respectively, and triple ligated into BamHI/SalI digested pBabe or pWZL 
using standard cloning procedures. To generate oncogenic mutant variants, 
the C-terminal ClaI/SalI fragment was subcloned into pBluescript. The 
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mutations were introduced using a site-directed mutagenesis kit (Stratagene) 
following the manufacturer’s recommendations and the mutated B-Raf 
fragments were cloned back into the pBabe or pWZL retroviral expression 
vectors. The following primers were used for the site directed mutagenesis: 
V600E-fwd 5’-gactttggtctagccacagAgaaatctcggtgg-3’, V600E-rev 5’-ccaccga 
gatttcTctgtggctagaccaaagtc, G466V-fwd 5’ cagagaattggatctgTgtcatttggaactg-
3’ and G466V-rev 5’-cagttccaaatgacAcagatccaattctctg-3’ (the introduced 
nucleotide changes are highlighted by capital letters). Δ3-B-Raf-pBabe, Δ3-B-
RafV600E-pBabe, and Δ3-B-RafG466V-pBabe were generated by replacing the N-
terminal BamHI-BamHI fragment of the full length cDNA with a sub-cloned N-
terminal fragment lacking the 99 nucleotides in exon 3. This fragment was 
PCR amplified from mouse cDNA. All cloned cDNAs were sequenced to 
confirm that no unwanted nucleotide changes were introduced. Sequencing 
was performed by the Sequencing cores of the University of Pennsylvania 
and the Cambridge Research Institute. Expression vectors pEFm-A-Raf, 
pEFm-Raf1.6, pEFm-Raf1.6-K375M, and pEFm-Raf1.6-S338A were kindly 
provided by Dr. R. Marais. pBabe-NrasG12D was generated by Dr. C. Der and 
obtained from Addgene. pBabe-HrasG12V was generated by Dr. S. Lowe and 
obtained by Dr. D. Tuveson. pSuper-retro-scrambled and pSuper-retro-C-Raf 
were constructed by Dr. S. Hingorani and shRNA sequences were published 
previously (Hingorani et al., 2003). 
 
4.5 Cell lines and transfections 
HEK293T and NIH3T3 cells were obtained from ATCC and cultured in DMEM 
(Invitrogen) containing 10% fetal calf serum (Hyclone), 100U/mL Penicillin and 
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100ug/mL Streptomycin (both Invitrogen). NHEM were obtained from 
PromoCell and cultured in Melanocyte Growth Medium (PromoCell). 
Melanoma and human melanocyte cell lines (1205Lu, 451Lu, A375P, Malme 
3M, SKMel5, WM35, WM115, WM164, WM278, WM793, WM902B, WM982A, 
WM1552c, SbCl2, SKMel2, WM1346, WM1361A, Fom99) were a kind gift 
from Dr. M. Herlyn and cultured in DMEM containing 10% fetal calf serum, 
100U/mL Penicillin and 100ug/mL Streptomycin or Melanocyte Growth 
Medium (Fom99). Melan-a cells were a kind gift from Dr. D. Bennett and 
cultured in RPMI (Invitrogen) containing 10% fetal calf serum, 100U/mL 
Penicillin and 100ug/mL Streptomycin and 200uM TPA (Sigma). All cell lines 
were propagated using standard cell culture techniques. HEK293T cells were 
plated 24 hours before transient transfection using Fugene 6 (Roche) or 
Lipofectamine 2000 (Invitrogen). Transfections were performed following the 
manufacturer’s instructions. Transfected HEK293T cells were used for 
experiments 48 hours after transfection. NIH3T3 fibroblasts were infected with 
retroviruses produced in the Phoenix packaging cell line, in the presence of 
8ug/ml polybrene and selected with 2ug/ml puromycin or 200ug/ml 
hygromycin 48 hours after infection. For some experiments, cells were treated 
with Sorafenib (LC Laboratories) in DMSO at the indicated concentrations.  
 
4.6 Embryonic stem cell culture and targeting 
The 129Sv-derived embryonic stem (ES) cell line E14J was a kind gift from 
Dr. D. Adams. E14Js were cultured in Knock-out DMEM (Invitrogen) 
containing 15% ES cell tested fetal calf serum (Hyclone), 100U/mL Penicillin, 
100ug/mL Streptomycin, 2mM L-Glutamine (all Invitrogen), 0.001% beta-
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Mercaptoethanol and 1000U/ml leukemia-inhibitory factor (LIF, Chemicon). 
Cell culture plastics were pre-treated with 0.1% gelatin in PBS for 15 minutes 
and ES cells were cultured on a confluent layer of feeder cells. As feeder cells 
served growth arrested mouse embryonic fibroblasts derived from DR4 mice, 
which carry drug resistances for puromycin, hygromycin, G418, and 6-
thioguanine (Tucker et al., 1997). For ES cell targeting, cells were 
electroporated in 0.4cm cuvettes with 50ug of linearized targeting vector using 
a Biorad – Gene Pulsar II Excel (BioRad) set to 25uF and 800V. 
Electroporated ES cells were grown in media containing 3ug/ml puromycin, 
150ug/ml G418 or 2uM ganciclovir, depending on the selection cassette used 
for the targeting. 96 ES cell clones that survived selection were picked after 7 
days, trypsinized and plated in 96 well plates with feeder cells. After 3 days, 
clones were split into two 96 well plates. Clones in one 96 well plate were 
overgrown for DNA isolation. Clones in the other 96 well plate were 
trypsinized after 3 days, 2x freezing media added (60% FCS, 20% DMSO, 
20% ES cell media), overlaid with mineral oil and frozen at -80ºC. Positively 
targeted ES cell clones were injected into blastocysts by the CRI transgenic 
core to generate chimeric animals. 
 
4.7 Mouse embryonic fibroblasts
Mouse breedings were set up and females were checked for vaginal plugs the 
following days. The morning vaginal plugs were discovered was counted as 
0.5 dpc and embryos were isolated at 13.5-14.5 dpc. Embryos were washed 
in PBS and the amniotic sac, placenta and organs as well as the head, which 
was kept for genotyping the embryos, were removed. Embryos were then 
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finely chopped in 1ml of Trypsin using a razorblade and placed in a tissue 
culture incubator for 45 minutes. After incubation, Trypsin was quenched with 
20ml of MEF media (DMEM containing 10% FCS, penicillin and streptomycin) 
and cultured for two days. MEF lines were split once and frozen down at 
passage 2. Experiments with MEFs were carried out at passages 3-5 before 
the cells experienced tissue culture shock and underwent replicative 
senescence. To ablate conditional knock-out alleles and induce expression of 
conditional oncogenic alleles, MEFs were infected with adenoviral-Cre (Ad-
Cre) (~0.5-1.5x108 PFU, Transgenic Core, University of Iowa) or empty 
adenoviral control (Ad-Mock). Cells were incubated for three days post-
infection to allow recombination to occur. 
 
4.8 Proliferation, focus formation, soft agar and apoptosis assay 
For proliferation assays, 2.0-2.5x104 cells were plated in triplicates in 12 well 
plates and counted every day for 4 days (melan-a and NIH3T3 cells) or every 
other day for 7 days (WM793 cells and MEFs) using a Z2 Coulter Particle 
Count and Size Analyzer (Beckman Coulter). Alternatively, cells were 
incubated with 4uM BrdU for 6 hours and proliferating cells were detected 
using an anti-BrdU antibody (B&D) following the manufacturer’s instructions. 
For focus formation, 3x105 MEFs were plated in 6cm dishes or 5x103 MEFs 
were plated onto a confluent layer of growth arrested MEFs in 6 well plates. 
Cells were fixed with 70% ethanol after 12-21 days and stained with Giemsa. 
For soft agar assays, 5x104 cells were resuspended in 0.4% agar and plated 
over 0.8% agar. Colonies were stained with Giemsa after 3 weeks. For 
apoptosis assays, MEFs were treated with either 10ng/ml TNFα and 0.5ug/ml 
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cycloheximide or 5nM Staurosporine in DMEM containing 0.5% FCS for 8 
hours. The fraction of dead cells was determined using the CellTiter-Glo 
Luminescence Cell Viability Assay (Promega) according to the manufacturer’s 
recommendation and normalized to untreated control cells. 
 
4.9 Alkaline phosphatase staining 
MEFs derived from R26-LSL-FlpERt2; PLAP mice were infected with Ad-Cre 
and incubated with 10-100nM 4-Hydroxytamoxifen (4-OHT, Sigma) in DMSO 
for three days. Cells were fixed with 0.5% glutaraldehyde in PBS for 10 
minutes and endogenous alkaline phosphatase was inactivated by incubation 
in PBS at 65ºC for 30 minutes. Next, cells were rinsed in AP solution (100mM 
Tris pH8.5, 100mM NaCl, 50mM MgCl2) followed by staining with BM Purple 
(Roche) in the dark for 24 hours. Cells were air-dried and photographed using 
a Nikon Eclipse 100 microscope (Nikon). 
 
4.10 Immunoprecipitation 
Cells were washed twice with PBS and lysed in ice-cold RIPA lysis buffer 
(150mM NaCl, 50mM Tris-HCl pH7.4, 1mM EDTA, 1% Igepal CA-630). 400ug 
of total lysate were precleared for 20 minutes and then immunoprecipitated 
using 20ul of ANTI-FLAG M2 agarose beads (Sigma) or ANTI-HA agarose 
beads (Sigma) for 2 hours at 4°C. Beads were washed 4 times with RIPA lysis 
buffer and subjected to SDS-PAGE. For kinase assays, HA-B-RafV600E, HA-B-
Raf or myc-C-Raf were co-expressed with flag-B-RafV600E. HA-tagged and 
myc-tagged components of the complexes were immunoprecipitated for 6 
hours from 600ug of total lysate using ANTI-HA agarose beads or ANTI-myc 
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agarose beads, respectively. Complexes were eluted twice using 200ug/ml 
HA- or myc-peptide (both Sigma) in TBS for 30 minutes at 4°C, diluted with 
RIPA lysis buffer and subjected to a flag-IP overnight to isolate specific HA-
tagged/flag-tagged or myc-tagged/flag-tagged protein complexes. Beads were 
washed four times with RIPA lysis buffer and used in a MAPK sandwich 
kinase assay with 32P-γ-ATP, using MBP as final substrate (Millipore) 
according to the manufacturer’s recommendations. Kinase reactions were 
analyzed by SDS-PAGE and autoradiography to detect 32P-γ-labeled MBP. 
The beads from the flag-IP were used to detect the amount of 
immunoprecipitated flag-B-RafV600E by Western blotting and the phospho-MBP 
signal was normalized to immunoprecipitated flag-B-RafV600E. 
 
4.11 Western blotting 
Protein lysates and immunoprecipitates were separated on precast NuPAGE 
Novex 4-12% Bis-Tris gradient gels (Invitrogen), transferred onto a PVDF 
membrane (Millipore) and incubated overnight with one of the following 
primary antibodies: HA (1:2000), flag (1:2000), phospho-ERK1/2 (1:5000), 
ERK1/2 (1:3000), phospho-MEK1/2 (1:2000), MEK1/2 (1:2000) (all Cell 
Signaling), C-Raf (1:2000), B-Raf (1:2000), actin (1:6000) (all Santa Cruz 
Biotechnologies) panRas (1:2000) (Calbiochem), phospho-S338-C-Raf 
(1:1000), myc (1:2000), A-Raf (1:2000), DUSP4 (1:1000), DUSP6 (1:1000), 
Sprouty 2 (1:1000) (Abcam) in 5% milk in TBST. Membranes were incubated 
with secondary HRP-antibodies in 5% milk in TBST (Jackson 
ImmunoResearch) for one hour followed by signal detection with enhanced 
chemiluminescence and x-ray film (both Amersham). Alternatively, 
 39
membranes were incubated with Alexa Fluor secondary antibodies 
(Invitrogen) for one hour, and scanned using Li-Cor Odyssey. Signal was 
quantified using Odyssey software. 
 
4.12 Quantification of amount of Raf molecules per cell 
To determine the number of Raf molecules per cell, the same number of cells 
of each cell line was plated onto two plates. The next day, one plate was 
lysed in RIPA buffer, while the other plate was used to determine the cell 
number at the time-point the cells were lysed. Next, the protein concentrations 
of each lysate were determined and the amount of protein per cell and the 
number of cells per 20ug of total protein calculated. 20ug of total protein were 
then subjected to SDS-PAGE along with 4, 2, 1, 0.5, 0.2 ng of recombinant B-
Raf and C-Raf (Millipore) as a standard reference. Western blots for B-Raf 
and C-Raf were performed, the signal for the B-Raf and C-Raf standards were 
quantified using Image scan software and standard curves calculated for B-
Raf and C-Raf. These standard curves were used to calculate the amount of 
B-Raf or C-Raf protein per 20ug of total protein, which corresponded to a 
previously determined number of cells. From this the amount of B-Raf or C-
Raf protein per cell was calculated. Finally, the number of molecules per cell 
was calculated using the following formula: 
 
Avogadro’s number / (weight of one B-Raf or C-Raf molecule in ng / ng of B-
Raf or C-Raf per cell) = B-Raf or C-Raf molecules per cell.  
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Below as an example is the determination of B-Raf molecules per one 
WM793 melanoma cell: 1,907,000 cells were lysed in 100ul RIPA buffer. The 
protein concentration was determined as 2.012ug/ul, which corresponded to 
0.1055ng total protein per cell and 189,600 cells per 20ug total protein. After 
Western blotting the amount of B-Raf per 20ug of total protein was calculated 
as 1.715803ng, which corresponded to 9.0496x10-6ng of B-Raf molecules per 
cell. Using this number in the above equation gives the following: 
 
6.02x1023 / (9.6x1013 / 9.0496x10-6) = 56,750 B-Raf molecules per cell. 
 
4.13 RNA isolation and cDNA synthesis 
RNA was isolated from mouse tissues with TRIzol reagent (Invitrogen). 2-4ug 
RNA were used for cDNA synthesis using Ready-To-Go You-Prime First-
Strand Beads (Amersham Biosciences) following the manufacturer’s 
recommendations. 
 
4.14 DNA isolation and Southern blotting 
To isolate tail DNA, tails were incubated in 500ul tail buffer (50mM Tris-HCl 
pH8, 100mM EDTA, 100mM NaCl, 1% SDS, 0.5mg/ml Proteinase K) at 55°C 
overnight. 160ul 5M NaCl were added followed by centrifugation for 5 
minutes, and 500ul of supernatant were transferred to a fresh tube. DNA was 
precipitated with 340ul of Isopropanol, collected by centrifugation and washed 
in 70% Ethanol. Pellets were air-dried and resuspended in TE. To isolate ES 
cell DNA, overgrown clones were washed with PBS and incubated in tail 
buffer at 37°C for one hour. Twice the volume of ice-cold 96% Ethanol 
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saturated with NaCl was added to each well and the plates were shaken on 
an orbital shaker until DNA precipitates appeared. DNA was collected with 
pipette tips, transferred to tubes containing 70% Ethanol, centrifuged, air-dried 
and resuspended in TE. For some gene targetings, ES cell clones were pre-
screened by long range PCR using Phusion Taq polymerase (Phusion Hot 
Start High-Fidelity DNA Polymerase, New England Biolabs) following the 
manufacturer’s recommendations. Typically, one primer for these PCR 
reactions was located within the selection cassette whereas the other primer 
bound outside the homology arm. Thus, with the PCR product spanning the 
homology arm, false positives could be distinguished from correctly targeted 
clones. For Southern blotting, ~10ug of genomic DNA were digested overnight 
with 3ul of the appropriate restriction enzyme(s). DNA digests were separated 
on 0.8% TAE agarose gels. Gels were depurinated in 0.25M HCl for 25 
minutes and denatured in 1.5M NaCl, 0.5M NaOH for 25 minutes. DNA was 
then transferred onto positively charged Hybond N+ nylon membranes 
(Amersham) in 10x SSC overnight. After the DNA transfer, membranes were 
washed in 3x SSC, air-dried, and the DNA was cross-linked to membranes 
with 240 mJ/cm2 UVC irradiation. Membranes were incubated in ExpressHyb 
hybridization solution (Clontech) at 65°C for 30 minutes followed by 
hybridization of radio-labeled probe overnight at 65°C. Probes were designed 
to bind outside of the homology arms to distinguish between random 
integrants and correctly targeted clones. Probes were radio-labeled using the 
Prime-It II Random Primer Labeling Kit (Stratagene) and denatured by boiling 
for 5 minutes. After hybridization, membranes were washed twice with 2x 
SSC, 0.2% SDS for 2 minutes at room temperature and once for 30 minutes 
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at 65°C. Air-dried membranes were exposed to X-ray film using intensifying 
screens at -80°C for up to 7 days. 
 
4.15 Mouse strains, genotyping and intranasal Ad-Cre instillation 
Conditional B-Raf knock-out mice (B-Raffl/fl) were generated by Dr. A. Silva 
(Chen et al., 2006) and kindly provided by Dr. M. Baccarini. Conditional C-Raf 
knock-out mice (Mikula et al., 2001) were created and provided by Dr. M. 
Baccarini. TyrCreERt2 mice were generated and provided by Dr. M. 
Bosenberg (Bosenberg et al., 2006) and LSL-KrasG12D mice were generated 
by Dr. D. Tuveson (Jackson et al., 2001). PLAP Flp reporter mice were 
created by Dr. S. Dymecki (Awatramani et al., 2001) and obtained from 
Jackson Laboratories. The generation of LSL-B-RafV619E and R26-LSL-
FlpERt2 mice is described in chapter 5.2. Initially, TyrCreERt2, PLAP, B-Raffl/fl 
and C-Raffl/fl mice were genotyped following the published PCR protocols. 
Later, genotyping was outsourced and all strains were genotyped by 
Transnetyx Inc. (www.transnetyx.com). For infection of mouse lungs with Ad-
Cre, mice were anesthetized using Isoflurane. 3x108 PFU of virus were 
precipitated in 500ul MEM (Invitrogen) and 2.4ul 2M CaCl2, according to the 
protocol used by the Jacks laboratory (DuPage et al., 2009; Jackson et al., 
2001, http://web.mit.edu/jacks-lab/). 50ul of MEM containing Ad-Cre were 
placed drop-wise onto one nostril of anesthetized mice until all liquid was 
inhaled. This procedure was repeated once so that each mouse was infected 
with ~6x107 PFU of Ad-Cre. For induction of Cre activity, mice carrying 
inducible CreERt2 alleles were intraperitoneally injected with 2mg Tamoxifen 
 43
(Sigma) in corn oil for 3 consecutive days or 4-Hydroxytamoxifen (25mg/ml in 
DMSO) was topically administered with a brush on two consecutive days. 
 
4.16 Histology, immunohistochemistry and quantification of lung tumor burden
Tissues were fixed in Formalin over-night and stored in 70% Ethanol. Fixed 
tissues were embedded, cut and stained with H&E by the CRI Histopathology 
core. Immunohistochemistry for Ki-67, cleaved Caspase 3 and phospho-ERK 
was also performed by the CRI Histopathology core. To determine the lung 
tumor burden of mice, total lung areas and neoplastic areas were calculated 
using Image J (Rasband, 1997-2008) and disease burden was represented as 
percent of total area. For characterization of individual neoplasms, data was 
represented as neoplasms/lung area. 
 
4.17 Statistical analysis 
All experiments were repeated at least three times and done in triplicates. 
Western blot experiments that showed modest changes were repeated five 
times and quantified each time. Data were accepted as reproducible when 
similar results with consistent changes were observed in all five experiments. 
Statistical analysis was performed using Student's t-test, P<0.05 was 
accepted as significant, * P<0.05, ** P<0.01. Data are shown as mean, error 
bars represent the standard deviation. 
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5. Results and Discussion 
 
 
 
 
 
 
5.1 C-Raf inhibits MAPK activation and transformation by 
B-RafV600E (Molecular Cell, in press) 
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Summary
Activating B-Raf mutations that deregulate the MAPK pathway commonly 
occur in cancer. Whether additional proteins modulate the enzymatic activity 
of oncogenic B-Raf is unknown. Here, we show that the proto-oncogene C-
Raf paradoxically inhibits B-RafV600E kinase activity through the formation of B-
RafV600E–C-Raf complexes. Although all Raf family members associate with 
oncogenic B-Raf, this inhibitory effect is specific to C-Raf. Indeed, a B-
RafV600E isoform with impaired ability to interact with C-Raf exhibits elevated 
oncogenic potential. Human melanoma cells expressing B-RafV600E display a 
reduced C-Raf:B-Raf ratio and further suppression of C-Raf increases MAPK 
activation and proliferation. Conversely, ectopic C-Raf expression lowers ERK 
phosphorylation and proliferation. Moreover, both oncogenic Ras and 
Sorafenib stabilize B-RafV600E–C-Raf complexes, thereby impairing MAPK 
activation. This inhibitory function of C-Raf on B-RafV600E-mediated MAPK 
activation may explain the lack of co-occurrence of B-RafV600E and oncogenic 
Ras mutations, and influence the successful clinical development of small 
molecule inhibitors for B-RafV600E-driven cancers. 
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Introduction
The mitogen-activated protein kinase (MAPK) pathway relays signals from the 
plasma membrane to the nucleus, thereby regulating the cell’s response to 
extracellular stimuli. This response encompasses diverse cell biological 
processes such as proliferation, growth, differentiation and apoptosis 
(Robinson and Cobb, 1997; Wellbrock et al., 2004a). To ensure proper control 
of these processes, the MAPK pathway is tightly regulated. Upon ligand 
binding to receptor tyrosine kinases, the small G protein Ras becomes 
activated and signals to the MAPK pathway and to several other effector 
pathways. Active Ras recruits Raf serine/threonine kinases (A-Raf, B-Raf, and 
C-Raf) to the plasma membrane, where they become activated by regulatory 
phosphorylation and dephosphorylation events, conformational changes and 
binding to other proteins (Wellbrock et al., 2004a). Active Raf phosphorylates 
MEK (for MAPK and extracellular signal-regulated kinase (ERK) kinase), 
which subsequently phosphorylates ERK. ERK translocates to the nucleus 
where it initiates diverse gene expression programs by activating transcription 
factor families such as ETS and AP-1. 
 
Since the MAPK pathway controls cellular processes that are often perturbed 
in human malignancy, it is not surprising that deregulation of the pathway is 
commonly observed in cancer. Indeed, activating Ras mutations are found in 
approximately 30% of human neoplasms (Bos, 1989). More recently, B-Raf 
mutations were reported in 7% of human cancers (Brose et al., 2002; Davies 
et al., 2002; Pollock and Meltzer, 2002), and two classes of B-Raf mutations 
have been identified. The majority of B-Raf mutations hyperactivate its kinase 
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function and B-RafV600E represents the most prominent example of this class. 
In contrast, three tumor-associated mutations (G466V, G466E, G596R) 
weaken the catalytic activity of B-Raf. These mutants have been proposed to 
stimulate C-Raf activity through physical interaction, thereby hyperactivating 
the MAPK pathway (Garnett et al., 2005; Wan et al., 2004). A link between 
mutations activating the MAPK pathway and cancer development was 
provided by genetically engineered mouse models. Mice expressing 
endogenous oncogenic Kras or B-Raf develop preneoplasms in several 
tissues (Karreth and Tuveson, 2009). Cells isolated from these mice display 
activation of the MAPK pathway and are partially transformed (Mercer et al., 
2005; Tuveson et al., 2004). Interestingly, despite possessing oncogenic 
potential in vivo (Kerkhoff et al., 2000) and in vitro (Heidecker et al., 1990; 
Stanton et al., 1989), activating mutations in C-Raf that lead to abnormal 
MAPK signaling are extremely rare and have only been observed in two 
cases of AML thus far (Zebisch et al., 2006). 
 
Raf proteins associate in response to Ras stimulation and complexes 
containing either two copies of the same Raf protein or one copy of two 
different Raf proteins have been observed (Farrar et al., 1996; Luo et al., 
1996; Weber et al., 2001). Indeed, wildtype B-Raf can signal to MEK/ERK by 
binding and activating C-Raf (Garnett et al., 2005), and B-Raf–C-Raf 
complexes possess higher kinase activity toward MEK than complexes 
containing only B-Raf or C-Raf (Rushworth et al., 2006). Additionally, impaired 
activity B-Raf mutants that require C-Raf to relay signals to MEK and ERK 
constitutively bind and activate C-Raf (Wan et al., 2004), leading to MAPK 
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hyperactivation (Garnett et al., 2005; Wan et al., 2004). Together, these 
findings imply that association of Raf proteins plays an important role in 
regulating MAPK signal intensity and may participate in controlling the 
biological output of MAPK activation. 
 
A crucial role for C-Raf in the activation of the MAPK pathway by B-Raf 
mutants with impaired catalytic function has been established. However, 
whether C-Raf is able to modulate B-RafV600E-mediated signaling is unknown. 
Here we report that C-Raf surprisingly inhibits B-RafV600E-induced MAPK 
activation and transformation through formation of a B-RafV600E–C-Raf 
complex with reduced kinase activity. Furthermore, oncogenic Ras stimulates 
activation of C-Raf and association with B-RafV600E to diminish MAPK 
signaling and proliferation, providing a rationale for the lack of co-occurrence 
of oncogenic Ras and B-RafV600E mutations in cancer.  Finally, incubation of 
B-RafV600E -expressing cells with the Raf kinase inhibitor Sorafenib results in 
stabilization of the C-Raf:B-Raf complex, providing additional insight into the 
mechanism of action of this and potentially other Raf kinase inhibitors. 
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Results
Effects of C-Raf on MAPK pathway activation by oncogenic B-Raf mutants 
To study modulation of oncogenic B-Raf signaling by C-Raf, mutant B-Raf 
and C-Raf were transiently expressed in HEK293T cells and ERK activation 
was examined. Concomitant expression of B-RafG466V and C-Raf promoted 
MAPK activation (Fig. 1A). In contrast, co-expression of B-RafV600E and C-Raf 
resulted in a marked decrease of phosphorylated ERK (pERK) levels 
compared to expression of B-RafV600E alone (Fig. 1A), suggesting a 
suppressive effect of C-Raf on B-RafV600E. We next determined whether C-Raf 
activity is required for suppression by co-expressing C-Raf mutants with 
severely reduced kinase activity with B-RafV600E. While C-RafK375M failed to 
suppress B-RafV600E signaling, B-RafV600E-mediated ERK activation was 
reduced by C-RafS338A (Fig. 1B). Interestingly, C-RafS338A but not C-RafK375M 
co-operated with B-RafG466V to promote MAPK pathway activation (Fig. 1B 
and Garnett et al., 2005), suggesting that Ras-induced phosphorylation of C-
Raf at Ser338 is not required for suppression of B-RafV600E and co-operation 
with B-RafG466V. The extent of interaction between C-RafK375M and B-Raf has 
been reported to be reduced, while binding of C-RafS338A to B-Raf is not 
affected by the mutation (Rushworth et al., 2006). Similarly, binding of C-
RafK375M, but not C-RafS338A, to B-RafV600E was markedly impaired (Fig. 1C), 
suggesting that binding to C-Raf is required, while C-Raf kinase activity is 
dispensable for suppression of B-RafV600E. Since C-RafK375M did not bind and 
suppress B-RafV600E, we reasoned that the direct association of C-Raf with B-
RafV600E inhibits the activity of B-RafV600E. To investigate this hypothesis, flag-
tagged B-RafV600E was co-expressed with HA-tagged B-RafV600E or myc-
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tagged C-Raf. To measure the kinase activity of different Raf complexes, 
sequential immunoprecipitation of associated Raf proteins was performed 
followed by MEK-ERK-MBP in vitro kinase assays using the purified 
complexes. The kinase activity of B-RafV600E–B-RafV600E complexes was 
comparable to the activity of B-RafV600E–B-RafWT complexes (data not shown). 
Notably, the kinase activity of B-RafV600E–C-Raf complexes was significantly 
reduced (Fig. 1D). Thus, C-Raf has an unexpected inhibitory function on 
MAPK pathway activation by associating with B-RafV600E, thereby reducing the 
kinase activity of the complex. 
 
Suppression of B-RafV600E signaling is specific to C-Raf and not due to 
activation of negative feedback loops 
We next determined whether wildtype B-Raf and A-Raf possess suppressive 
activities similar to C-Raf. Interestingly, co-expression of wildtype B-Raf did 
not suppress B-RafV600E (Fig. 2A). Conversely, wildtype B-Raf enhanced 
MAPK activation by B-RafG466V to similar levels as C-Raf (Fig. 2A). B-RafV600E 
was not inhibited by co-expression of A-Raf (Fig. 2B), indicating that C-Raf is 
the only Raf protein capable of suppressing B-RafV600E. Intriguingly, A-Raf 
failed to co-operate with B-RafG466V to promote MAPK pathway activation (Fig. 
2B). The binding efficiency of A-Raf to B-RafV600E was similar to that of C-Raf 
(Fig. 2C); hence, the lack of a suppressive function of A-Raf was not due to 
reduced complex formation of A-Raf with B-RafV600E. Thus, suppression of B-
RafV600E signaling is specific to C-Raf, while both C- and B-Raf can cooperate 
with B-RafG466V. To exclude the possibility that co-expression of oncogenic B-
Raf and C-Raf activates negative feedback loops and thus leading to reduced 
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pERK expression, we analyzed phosphorylation of MEK to more accurately 
determine the activity of B-Raf mutants. Similar to the results regarding pERK, 
co-expression of C-Raf and B-RafV600E diminished MEK activation, while 
concomitant expression of C-Raf and B-RafG466V further induced 
phosphorylation of MEK when compared to expression of the respective B-
Raf mutants alone (Fig. 2D). Finally, expression levels of dual specificity 
phosphatases (DUSP4 and DUSP6) as well as Sprouty 2, known negative 
modulators of the MAPK pathway, were unchanged upon expression of B-
RafV600E or B-RafG466V alone or in combination with C-Raf (Fig. 2E). Therefore, 
modulation of oncogenic B-Raf-induced MAPK pathway activation by C-Raf is 
not mediated by activation of negative feedback loops. 
 
Interaction of C-Raf and oncogenic B-RafV600E impairs cellular transformation
We identified a murine splice form of B-Raf (termed Δ3-B-Raf) that lacked 33 
amino acids within exon 3. The sequence of Δ3-B-Raf has been noted in 
Genbank for mouse (e.g. NM_139294) and rat (e.g. XM_231692). Δ3-B-Raf 
interacts with C-Raf less efficiently (Suppl. Fig. 1-3) and was utilized to study 
the effect of B-Raf–C-Raf interaction on cellular transformation by oncogenic 
B-Raf. Decreased basal and HrasG12V-induced binding of Δ3-B-RafG466V to C-
Raf was accompanied by reduced activation of the MAPK pathway (Suppl. 
Fig. 4A, B). Moreover, stimulation of proliferation and anchorage-independent 
growth in soft agar by Δ3-B-RafG466V was less pronounced when compared to 
B-RafG466V (Suppl. Fig. 4C, D). These findings further support the notion that 
complex formation of C-Raf and B-RafG466V promotes activation of the MAPK 
pathway. 
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 We next determined whether reduced interaction with C-Raf increased the 
oncogenic potential of B-RafV600E. First, expression in HEK293T cells showed 
that, in contrast to impaired activity mutants (Garnett et al., 2005), B-RafV600E 
or Δ3-B-RafV600E only very inefficiently interact with endogenous C-Raf (Fig. 
3A). Co-expression with HrasG12V induced association of full length B-RafV600E 
and, to a lesser extent, of Δ3-B-RafV600E with C-Raf (Fig. 3A). Strikingly, 
HrasG12V-mediated complex formation of C-Raf with B-RafV600E diminished B-
RafV600E-driven phosphorylation of ERK, and reduction of pERK levels was 
less pronounced in cells expressing Δ3-B-RafV600E compared to full length B-
RafV600E (19% vs. 26% reduction, Fig. 3A). Ectopic expression of B-RafV600E 
has been shown to transform the immortalized melanocyte cell line melan-a 
(Wellbrock et al., 2004b), confirming B-Raf’s oncogenic potential in melanoma 
(Davies et al., 2002). Therefore, full length B-RafV600E and Δ3-B-RafV600E were 
stably expressed in melan-a cells to assess the role of B-RafV600E–C-Raf 
complex formation on cellular transformation. Δ3-B-RafV600E expression 
stimulated ERK activation and TPA-independent proliferation more efficiently 
than B-RafV600E (Fig. 3B and 3C). Moreover, anchorage-independent growth 
promoted by B-RafV600E was further increased by Δ3-B-RafV600E (Fig. 3D). 
Similar increases in transformation potential conferred by Δ3-B-RafV600E were 
observed in NIH3T3 fibroblasts (data not shown). Together, these data 
demonstrate that C-Raf-mediated inhibition of B-RafV600E-stimulated MAPK 
signaling and cell transformation is proportional to the efficiency of B-
RafV600E–C-Raf complex formation. 
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Human melanoma cells circumvent suppression of B-RafV600E by reducing the 
C-Raf:B-Raf ratio 
To investigate whether the antagonistic function of C-Raf towards B-RafV600E 
was apparent in melanoma, the relative amounts of C-Raf and B-Raf were 
assessed in a panel of human melanoma cell lines and compared to a human 
melanocyte cell line (normal human epidermal melanocytes, NHEM). All 
investigated melanoma cell lines harboring B-RafV600E displayed a reduced C-
Raf:B-Raf ratio when compared to NHEM (Fig. 4A). In contrast, Nras mutant 
cells exhibited similar C-Raf levels but lower B-Raf levels than NHEM, 
resulting in an increased C-Raf:B-Raf ratio (Fig. 4A). These results indicate 
that the reduction of C-Raf levels relative to B-Raf is specific to melanoma 
cells harboring B-RafV600E and does not occur in cell lines that activate the 
MAPK pathway through other means. To assess whether relative Raf levels in 
NHEM are representative of melanocytes, expression of B-Raf and C-Raf was 
compared to another human melanocytes cell line, Fom99. C-Raf expression 
in Fom99 melanocytes was increased compared to NHEM, resulting in a 
higher C-Raf:B-Raf ratio in these cells (Suppl. Fig. 5A). Thus, the reduction of 
the C-Raf:B-Raf ratios in B-RafV600E mutant melanoma cell lines compared to 
melanocytes is a general finding.  For the observed reduction of the C-Raf:B-
Raf ratio in B-RafV600E melanoma cells to be biologically relevant, C-Raf and 
B-Raf molecules should be present at comparable levels in such cells. To 
address this, the quantity of B-Raf and C-Raf molecules per cell was 
determined in several melanoma cell lines using recombinant B-Raf and C-
Raf as reference standards (Suppl. Fig. 5B). Importantly, the amounts of B-
Raf and C-Raf molecules expressed per cell were similar in all investigated 
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cell lines (Suppl. Fig. 5C). Finally, A-Raf expression was not significantly 
changed and did not correlate with B-Raf mutation status (Suppl. Fig. 5D), 
which is consistent with the lack of suppressive activity towards B-RafV600E.  
Thus, by altering the C-Raf to B-Raf stoichiometry, human melanoma cells 
harboring B-RafV600E may circumvent suppression of B-RafV600E-induced 
MAPK activation. 
 
Altering C-Raf expression levels in melanoma cell lines carrying B-RafV600E 
impacts on MAPK signaling and proliferation 
To analyze whether further reducing the expression levels of C-Raf affects on 
MAPK activation and cell proliferation in human B-RafV600E and Nras mutant 
melanoma cell lines, C-Raf was depleted using RNAi. C-Raf protein levels 
were decreased significantly following knock-down, while B-Raf levels were 
unchanged (Fig. 4B). Interestingly, abrogation of C-Raf expression in the B-
RafV600E expressing cell lines WM793, WM164, and WM983A promoted 
increased ERK phosphorylation (Fig. 4B). In contrast, decreased pERK levels 
were observed upon C-Raf depletion in the N-Ras-mutant cell line SKMel2 
(Fig. 4B), consistent with published data (Dumaz et al., 2006). Next, the effect 
of enhanced MAPK signaling on proliferation of melanoma cells was 
determined by labeling shRNA-treated cells with BrdU. C-Raf depletion was 
accompanied by a moderate increase in proliferation of WM793, WM164, and 
WM983A cells, whereas Nras mutant cells exhibited reduced proliferation 
upon C-Raf depletion (Fig. 4C). Since C-Raf expression is reduced in many 
B-Raf mutant human melanoma cell lines, we sought to determine the effect 
of increased C-Raf levels on MAPK pathway activation and proliferation in 
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such cells.  Consistent with our prior findings regarding the properties of C-
Raf in B-RafV600E melanoma cells, we found that multiple melanoma cell lines 
would not support the stable ectopic expression of C-Raf.  Therefore, the 
melanoma cell line WM793 was examined immediately following transfection 
with C-Raf, demonstrating that increased C-Raf levels can directly inhibit both 
the MAPK pathway (Fig. 4D) and cellular proliferation (Fig. 4E). Therefore, C-
Raf possesses a suppressive function in B-RafV600E melanoma cells. 
 
Oncogenic Ras impairs B-RafV600E signaling through activation of C-Raf 
In human cancer, oncogenic Ras and B-RafV600E mutations do not co-occur, 
while tumors harboring Ras and non-V600E B-Raf mutations have been 
reported (Thomas et al., 2007). Intriguingly, B-RafV600E–C-Raf association was 
increased upon HrasG12V co-expression (Fig. 2B). Hence, we hypothesized 
that oncogenic Ras could inhibit B-RafV600E-mediated MAPK signaling by 
activating C-Raf and promoting B-RafV600E–C-Raf interaction. Accordingly, 
HrasG12V was expressed in NIH3T3 fibroblasts either alone or together with B-
RafV600E. Expression of HrasG12V resulted in elevated levels of pS338-C-Raf, 
confirming increased C-Raf activation by HrasG12V (Fig. 5A). In addition, B-
Raf–C-Raf complexes and pERK levels were more abundant in cells 
expressing HrasG12V (Fig. 5A). Thus, oncogenic Ras induces MAPK signaling 
in fibroblasts through C-Raf activation and induction of B-Raf–C-Raf 
complexes. In contrast, HrasG12V-mediated induction of B-Raf–C-Raf 
complexes in NIH3T3 fibroblasts expressing B-RafV600E correlated with 
diminished MAPK pathway activation (Fig. 5B). Moreover, increased 
proliferation conferred by either B-RafV600E or HrasG12V was negated by 
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concomitant expression of both oncogenes in NIH3T3 cells (Fig. 5C). To 
ascertain that complex formation is not due to overexpression of oncogenic B-
Raf, similar experiments were performed in WM793 melanoma cells that 
express endogenous B-RafV600E. Consistent with the data obtained in NIH3T3 
fibroblasts, expression of NrasG12D in WM793 cells stimulated B-Raf–C-Raf 
interaction and resulted in reduced pERK levels (Fig. 5D). Moreover, WM793 
cells expressing NrasG12V proliferated less than cells transfected with a vector 
control (Fig. 5E). Similarly, ectopic expression of HrasG12V in WM793 
melanoma cells increased B-Raf–C-Raf complex formation, which correlated 
with decreased levels of pERK and proliferation (Suppl. Fig. 6A, B), indicating 
that different Ras oncoproteins are capable of antagonizing B-RafV600E. These 
findings provide a potential explanation for the exclusivity of Ras and B-
RafV600E mutations in human cancers. 
 
Sorafenib stabilizes B-RafV600E–C-Raf complexes 
Raf kinase inhibitors have been developed as targeted therapeutics for 
melanoma, and therefore we investigated whether such compounds could 
influence B-RafV600E–C-Raf complex formation. Indeed, treatment of HEK293T 
cells expressing flag-B-RafV600E and myc-C-Raf with the Raf inhibitor 
Sorafenib at concentrations that inhibited MAPK signaling (0.3-3 uM) resulted 
in increased formation of B-RafV600E–C-Raf complexes (Fig. 6A, B). 
Surprisingly, low concentrations of Sorafenib increased rather than inhibited 
ERK phosphorylation (Fig. 6A, B). To exclude overexpression artifacts as a 
possible explanation for this observation, the response to Sorafenib was 
examined in WM164, A375P and SKMel2 melanoma cells and mouse 
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embryonic fibroblasts expressing endogenous B-RafV619E. We found similar 
patterns of B-RafV600E–C-Raf complex stabilization and pERK inhibition at high 
doses of Sorafenib in all examined cell lines. (Suppl. Fig. 6). However, 
increased pERK levels at low doses of Sorafenib were only observed in B-
RafV600E mutant cells (WM164, A375P, and MEFs) but not in SKMel2 cells, 
which carry an N-Ras mutation (Supp. Fig. 6). To determine whether 
stabilization of B-RafV600E–C-Raf complexes leads to inhibition of MAPK 
activation, the sensitivity of Δ3-B-RafV600E to Sorafenib was assessed. 
Sorafenib increased association of C-Raf with Δ3-B-RafV600E in a dose-
dependent manner; however, the amount of complexes was lower compared 
to Sorafenib-induced full length B-RafV600E–C-Raf complexes (Fig. 6C). 
Moreover, cells expressing Δ3-B-RafV600E were more resistant to high 
concentrations of Sorafenib than FL-B-RafV600E-expressing cells. While 
treatment with 3uM Sorafenib significantly reduced pERK levels compared to 
the 0.3uM dose when FL-B-RafV600E was expressed, no pronounced decrease 
in pERK levels was observed in Δ3-B-RafV600E-expressing cells at these 
concentrations (Fig. 6D). Thus, promoting suppression of B-RafV600E through 
stabilization of B-RafV600E–C-Raf complexes may be an additional mode of 
action of Sorafenib. We reasoned that the increased pERK levels noted at low 
doses of Sorafenib may be due to induction of active protein complexes 
containing only B-RafV600E. To examine this, HA-B-RafV600E and flag-B-
RafV600E were co-expressed and cells treated with increasing concentrations 
of Sorafenib. Indeed, Sorafenib induced HA-B-RafV600E–flag-B-RafV600E 
complexes in a dose-dependent manner (Fig. 6E). Elevation of pERK levels 
correlated with HA-B-RafV600E–flag-B-RafV600E complex formation in response 
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to low doses Sorafenib (0.003-0.03uM). Interestingly, high doses of the Raf 
inhibitor could not diminish pERK levels below vehicle-treated control levels in 
cells expressing B-RafV600E alone (Fig. 6E). These findings suggest that 
Sorafenib-induced stabilization of B-RafV600E–C-Raf complexes with low 
kinase activity contributes to the therapeutic activity of this small molecule 
inhibitor.  
 60
Discussion 
Activating mutations in Ras and B-Raf are commonly found in cancer and 
lead to deregulation of the MAPK pathway. Investigating this aberrant 
regulation of the MAPK signaling cascade in cancer could identify useful 
therapeutic targets to combat the disease. In this study, we report a 
suppressive function of the proto-oncogene C-Raf on oncogenic B-RafV600E. 
 
We found that C-Raf suppresses B-RafV600E through the formation of B-
RafV600E–C-Raf complexes that display markedly decreased kinase activity, 
leading to impaired activation of MEK/ERK. This finding was surprising 
because B-Raf–C-Raf complexes were reported to possess higher kinase 
activity towards MEK than B-Raf–B-Raf and C-Raf–C-Raf complexes 
(Rushworth et al., 2006). A potential explanation could be the restriction of B-
RafV600E protein dynamics and therefore catalytic activity by its association 
with C-Raf. As wildtype A-Raf or B-Raf bind to B-RafV600E but don’t inhibit the 
activity of B-RafV600E, such complexes are likely distinct in their quaternary 
structure or contain different additional binding partners compared to the B-
RafV600E–C-Raf complexes. Whether C-Raf has a similar inhibitory influence 
on wildtype B-Raf-mediated MAPK activation in cells is incompletely 
understood. Indeed, genetic ablation of C-Raf increases B-Raf activity and 
phosphorylation of MEK in fibroblasts (Mikula et al., 2001), indicating that C-
Raf may negatively modulate MAPK signaling under certain conditions. These 
data suggest that the composition and abundance of Raf complexes play 
pivotal roles in regulating the extent of MAPK pathway activation under 
normal and pathological conditions. The relative cellular amounts of B-Raf 
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and C-Raf may affect the formation of Raf complexes and thus the 
susceptibility of certain cell types to transformation by different oncogenic B-
Raf mutants. This is supported by the fact that the occurrence of the V600E 
mutation is relatively rare in cancers that more commonly carry impaired 
activity B-Raf mutations, such as the lung (see COSMIC database for B-Raf 
mutation data in cancer; http://www.sanger.ac.uk/genetics/CGP/cosmic/). 
 
C-Raf has been previously demonstrated to antagonize other serine/threonine 
kinases through physical interaction. Binding of C-Raf to the proapoptotic 
kinases MST2 (O'Neill et al., 2004) and ASK1 (Chen et al., 2001) prevents 
their activation and protects cells from apoptosis. Moreover, C-Raf inhibits 
Rok-α, thereby regulating cell motility and death (Piazzolla et al., 2005). 
Similar to MST2 (O'Neill et al., 2004), suppression of B-RafV600E is specific to 
C-Raf as wildtype B-Raf could not inhibit B-RafV600E. C-Raf exerts its inhibitory 
functions on MST2, ASK1 and Rok-α independent of its kinase activity and 
MEK/ERK signaling. To address whether C-Raf kinase activity is required for 
suppression of B-RafV600E, we determined MAPK activation by B-RafV600E in 
the presence of two C-Raf mutants with severely impaired catalytic activity. 
Interestingly, suppression of B-RafV600E by wildtype and mutant C-Raf 
correlated with the efficiency of complex formation rather than C-Raf activity. 
Moreover, we did not observe changes in Ser/Thr phosphorylation of 
immunoprecipitated B-RafV600E when co-expressed with C-Raf (data not 
shown) and thus kinase activity appears to be dispensable for the antagonistic 
effect of C-Raf. Reduced binding of C-RafK375M to B-Raf has been noted 
before (Rushworth et al., 2006) and could be due to a conformational change 
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induced by the K375M mutation, thereby impairing interaction. In contrast, the 
association of C-Raf with MST2, ASK1, and ROK-α is unaffected by the 
K375M mutation. Whether the catalytic lysine at position 375 of C-Raf is 
crucial for complex formation with B-Raf remains to be determined. Therefore, 
these findings suggest that the interaction of C-Raf with B-RafV600E directly 
lowers the kinase activity of B-RafV600E. 
 
We found that the C-Raf expression levels are reduced relative to B-Raf 
levels in human melanoma cell lines expressing B-RafV600E. Interestingly, cells 
derived from early tumor stages (radial and vertical growth phase) contained 
decreased C-Raf protein levels, while metastasis-derived cell lines harbored 
increased B-Raf protein levels and therefore a reduced C-Raf:B-Raf ratio. 
Previously, C-Raf mRNA levels were found to be lower in B-RafV600E 
melanoma cells compared to cells expressing wildtype B-Raf, suggesting 
transcriptional regulation as a potential mechanism of C-Raf reduction (Pavey 
et al., 2004),. We have confirmed that the B-Raf mRNA levels are higher than 
that of C-Raf in B-RafV600E expressing melanoma cells (data not shown), 
although translational and post-translational processes may also participate in 
our findings.  Nonetheless, the reduced ratio of C-Raf:B-Raf protein levels in 
B-RafV600E-expressing melanoma cells relative to melanocytes is likely to 
alleviate suppression of B-RafV600E. This hypothesis is substantiated by our 
observation that C-Raf and B-Raf molecules are present at near-equimolar 
amounts in these cells. Therefore, changes in the stoichiometry could impact 
the formation of Raf complexes. Further evidence for a suppressive function 
of C-Raf in B-RafV600E-expressing human melanoma cell lines comes from the 
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observation that stable cell lines expressing ectopic C-Raf or ectopic Ras 
could not be isolated.  Invariably, expression of these cDNAs was rapidly 
downregulated or lost, indicating that B-RafV600E–C-Raf complex formation by 
forced expression of high C-Raf or Ras levels is not tolerated by these cells. 
Together, these findings support the premise that B-RafV600E-expressing cells 
circumvent C-Raf’s antagonistic function by reducing C-Raf levels relative to 
B-Raf, thereby creating an intracellular environment that facilitates 
hyperactivation of the MAPK pathway and cellular transformation. 
 
B-RafV600E and oncogenic Ras mutations are mutually exclusive in human 
cancer, which has previously been attributed to redundant MAPK pathway 
activation by the two oncogenes. We demonstrate here that oncogenic Ras 
activates C-Raf, leading to an interaction with B-RafV600E and inhibition of its 
catalytic activity. Suppression of MAPK pathway activation by two oncogenic 
Ras mutants (HrasG12V and NrasG12D) was observed in melanoma cells and 
fibroblasts expressing B-RafV600E, indicating that Ras-mediated inhibition of B-
RafV600E is not limited to one specific cell type or Ras protein. Indeed, mutual 
exclusivity of B-RafV600E and oncogenic Ras appears to be a universal 
phenomenon, irrespective of cancer type. Interestingly, non-B-RafV600E 
mutations co-occur with Ras mutations (Thomas et al., 2007), consistent with 
the increased association of B-RafG466V with C-Raf and ERK activation upon 
expression of HrasG12V as observed in this study. C-Raf activation by impaired 
activity mutant B-Raf occurs independently of Ras (Garnett et al., 2005); 
however, we propose that C-Raf activation is further increased by oncogenic 
Ras, thereby enhancing MAPK signaling. Thus, co-occurrence of oncogenic 
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Ras and impaired activity mutant B-Raf cooperates to deregulate the MAPK 
pathway, resulting in signal intensities that may enhance oncogenesis of 
certain tumor types. 
 
Sorafenib inhibits C-Raf more potently than B-Raf and B-RafV600E (Wilhelm et 
al., 2004). While high doses of Sorafenib inhibited MAPK signaling, lower 
doses partially rescued C-Raf-induced suppression of B-RafV600E signaling 
(Fig. 6). Importantly, cells expressing either Δ3-B-RafV600E or no ectopic C-Raf 
were more resistant to Sorafenib at high doses. Therefore, the Sorafenib-
mediated interaction of C-Raf with B-RafV600E and the consequential decrease 
in catalytic activity may be an additional mode of action of Sorafenib. 
Increased MAPK pathway activation at low concentrations may be due to 
Sorafenib-induced association of B-RafV600E with wildtype or mutant B-Raf, 
which could augment B-RafV600E activity. Indeed, B-RafV600E–B-RafV600E 
complexes were induced at lower concentrations of Sorafenib than B-
RafV600E–C-Raf complexes. When Sorafenib-induced formation of B-RafV600E–
B-RafV600E complexes was determined, only the amount of HA-tagged B-
RafV600E bound to flag-tagged B-RafV600E was examined, whereas complexes 
consisting of only one species of tagged B-RafV600E were disregarded. The 
actual amount of complexes containing only B-RafV600E is therefore much 
higher than indicated by the experimental approach. Moreover, low levels of 
Sorafenib did not increase pERK levels in N-Ras mutant SKMel2 cells (Suppl. 
Fig. 7), indicating that mutant N-Ras-induced activation of the MAPK pathway 
is not enhanced by stabilization of wildtype B-Raf–B-Raf complexes. Thus, 
low concentrations of Sorafenib may promote rather than inhibit B-RafV600E 
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signaling through stabilization of B-RafV600E–B-RafV600E complexes. Indeed, 
Sorafenib has performed poorly in clinical trials thus far and showed equal 
efficacy in B-RafV600E and B-RafWT tumors (Eisen et al., 2006). Tumors 
carrying impaired activity mutant B-Raf, however, were not evaluated and 
may be more responsive to pan-Raf inhibitors such as Sorafenib. Therefore, 
determining the B-Raf mutational status could be imperative for the right 
choice of treatment. Our finding that proto-oncogenic C-Raf exhibits 
suppressive activity towards B-RafV600E should encourage investigations into 
the development of inhibitors that efficiently and selectively stabilize B-
RafV600E–C-Raf complexes for the treatment of cancers harboring this 
mutation. 
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Experimental Procedures 
 
Plasmids 
B-Raf was PCR amplified from mouse cDNA, a flag-tag or HA-tag introduced 
at the C-terminus and cloned into pBabe-puro or pWZL-hygro, respectively. 
Mutant variants were generated using a site-directed mutagenesis kit 
(Stratagene). 
 
Cell lines and transfections  
HEK293T and NIH3T3 cells were obtained from ATCC and cultured in DMEM 
(Invitrogen) containing 10% fetal calf serum (Hyclone), 100U/mL Penicillin and 
100ug/mL Streptomycin (both Invitrogen). NHEM were obtained from 
PromoCell and cultured in Melanocyte Growth Medium (PromoCell). 
Melanoma cell lines were a kind gift from M. Herlyn (Wistar Institute, 
Philadelphia) and cultured in DMEM containing 10% fetal calf serum, 
100U/mL Penicillin and 100ug/mL Streptomycin. Melan-a cells were a kind gift 
from D. Bennett (London) and cultured in RPMI (Invitrogen) containing 10% 
fetal calf serum, 100U/mL Penicillin and 100ug/mL Streptomycin and 200uM 
TPA (Sigma). HEK293T cells were plated 24 hours before transient 
transfection using Fugene 6 (Roche) or Lipofectamine 2000 (Invitrogen). 
Transfected HEK293T cells were used for experiments 48 hours after 
transfection. NIH3T3 fibroblasts were infected with retroviruses produced in 
the Phoenix packaging cell line, in the presence of 8ug/ml polybrene and 
selected with puromycin or hygromycin 48 hours after infection. For knock-
down experiments, we used the pSuper-retro-puro vector containing short 
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hairpins targeting human C-Raf and a scrambled control. shRNA sequences 
were published previously (Hingorani et al., 2003). 
 
Immunoprecipitation 
Cells were washed twice with PBS and lysed in ice-cold RIPA lysis buffer. 
400ug of total lysate were precleared for 20 minutes and then 
immunoprecipitated with 20ul of ANTI-FLAG M2 agarose beads (Sigma) or 
ANTI-HA agarose beads (Sigma) for 2 hours at 4°C. Beads were washed 4 
times with RIPA lysis buffer and subjected to SDS-PAGE. For kinase assays, 
HA-B-RafV600E, HA-B-Raf, myc-C-Raf, or myc-C-RafK375M were co-expressed 
with flag-B-RafV600E. HA-tagged and myc-tagged components of the 
complexes were immunoprecipitated for 6 hours from 600ug of total lysate 
using ANTI-HA agarose beads or ANTI-myc agarose beads, respectively. 
Complexes were eluted twice using 200ug/ml HA- or myc-peptide in TBS for 
30 minutes at  4°C, diluted with RIPA lysis buffer and subjected to a flag-IP 
overnight to isolate specific HA-tagged/flag-tagged or myc-tagged/flag-tagged 
protein complexes. Beads were washed four times with RIPA lysis buffer and 
used in a MAPK sandwich kinase assay with 32P-γ-ATP, using MBP as final 
substrate (Millipore) according to the manufacturer’s recommendations. 
Kinase reactions were analyzed by SDS-PAGE and autoradiography to detect 
32P-γ-labeled MBP. The beads from the flag-IP were used to detect the 
amount of immunoprecipitated flag-B-RafV600E by Western blotting and the 
phospho-MBP signal was normalized to immunoprecipitated flag-B-RafV600E. 
 
Western blotting 
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Protein lysates and immunoprecipitates were separated on precast NuPAGE 
Novex 4-12% Bis-Tris gradient gels (Invitrogen), transferred onto a PVDF 
membrane (Millipore) and incubated overnight with one of the following 
primary antibodies: HA, flag, phospho-ERK1/2, ERK1/2, phospho-MEK1/2, 
MEK1/2 (all Cell Signaling), C-Raf, B-Raf, actin (all Santa Cruz 
Biotechnologies) panRas (Calbiochem), phospho-S338-C-Raf, myc, A-Raf, 
DUSP4, DUSP6, Sprouty 2 (both Abcam). Membranes were incubated with 
secondary HRP-antibodies (Jackson ImmunoResearch) for one hour followed 
by signal detection with enhanced chemiluminescence and x-ray film (both 
Amersham). Alternatively, membranes were incubated with Alexa Fluor 
secondary antibodies (Invitrogen) for one hour, and scanned using Li-Cor 
Odyssey. Signal was quantified using Odyssey software. 
 
Proliferation and soft agar assays 
2.0-2.5x104 cells were plated in triplicates in 12 well plates and counted every 
day for 4 days for proliferation of melan-a and NIH3T3 cells or counted every 
other day for 7 days for proliferation of WM793 cells. Alternatively, cells were 
incubated with BrdU for 6 hours and proliferating cells detected using an anti-
BrdU antibody (B&D) following the manufacturer’s instructions.  For soft agar 
assays, 5x104 cells were resuspended in 0.4% agar and plated over 0.8% 
agar. Colonies were stained with Giemsa after 3 weeks. 
 
RNA isolation, cDNA synthesis, and PCR analysis 
RNA was isolated from mouse tissues with TRIzol reagent (Invitrogen). 2-4ug 
RNA were used for cDNA synthesis using Ready-To-Go You-Prime First-
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Strand Beads (Amersham Biosciences) following the manufacturer’s 
recommendations. For PCR analysis of exon 3, primers binding to exon 2 and 
4 were designed. 
 
Statistical analysis 
All experiments were repeated at least three times and done in triplicates. 
Western blot experiments that showed modest changes were repeated five 
times and quantified each time. Data were accepted as reproducible when 
similar results with consistent changes were observed in all five experiments. 
Statistical analysis was performed using Student's t-test, P<0.05 was 
accepted as significant, * P<0.05, ** P<0.01. Data are shown as mean, error 
bars represent the standard deviation.  
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Figures 
 
Figure 1: C-Raf inhibits B-RafV600E kinase activity. (A) Effect of C-Raf on ERK 
activation mediated by B-Raf mutants. Levels of pERK in HEK293T cells 
expressing flag-B-RafV600E or flag-B-RafG466V alone or together with myc-C-Raf 
were determined by Western blotting. Densitometric analyses for pERK levels 
are shown. (B) Effect of C-Raf mutants with impaired kinase activity on ERK 
activation by B-RafV600E or B-RafG466V. Levels of pERK in B-Raf mutant cells 
expressing either wildtype C-Raf, C-RafK375M or C-RafS338A were determined 
by Western blotting. (C) Reduced association of C-RafK375M with B-RafV600E. 
C-Raf, C-RafK375M or C-RafS338A were co-immunoprecipitated with B-RafV600E 
and levels of bound protein assessed by Western blotting. (D) B-RafV600E–C-
Raf complexes display reduced kinase activity. Schematic depicts the 
sequential immunoprecipitation approach. Amount of MBP phosphorylation 
with 32P-γ-ATP by B-RafV600E–B-RafV600E complexes or B-RafV600E–C-Raf 
complexes was determined by SDS-PAGE and autoradiography. Equal levels 
of input proteins were verified by Western blotting. 
 
Figure 2: B-RafV600E signaling is not inhibited by A-Raf, wildtype B-Raf or 
activation of negative feedback loops. (A) Effect of wildtype B-Raf on ERK 
activation mediated by B-Raf mutants. Levels of pERK in cells expressing 
flag-B-RafV600E or flag-B-RafG466V with or without HA-B-RafWT were determined 
by Western blotting. (B) Effect of A-Raf on ERK activation mediated by B-Raf 
mutants. Levels of pERK in cells expressing flag-B-RafV600E or flag-B-RafG466V 
with or without myc-A-Raf were determined by Western blotting. (C) A-Raf 
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forms complexes with B-RafV600E. myc-C-Raf or myc-A-Raf were 
immunoprecipitated from HEK293T cells co-expressing flag-B-RafV600E and 
levels of bound B-RafV600E determined by Western blotting. (D) C-Raf 
decreases MEK activation by B-RafV600E and augments MEK activation by B-
RafG466V. Levels of pMEK in cells expressing flag-B-RafV600E or flag-B-RafG466V 
with or without myc-C-Raf were determined by Western blotting. (E) Negative 
feedback loops are not activated upon co-expression of B-RafV600E and C-Raf. 
C-Raf was expressed in cells expressing B-Raf mutants and levels of DUSP4, 
DUSP6 and Sprouty 2 were analyzed by Western blotting. Lysates of 
HrasG12V-transformed NIH3T3 fibroblasts served as positive controls.  
 
Figure 3: Reduced interaction with C-Raf promotes transformation by Δ3-B-
RafV600E. (A) HrasG12V-induced association of C-Raf with full length (FL-) B-
RafV600E and Δ3-B-RafV600E in HEK293T cells. Immunoprecipitated amounts of 
C-Raf as well as levels of pERK, B-Raf, C-Raf, and HrasG12V in the lysates 
were determined by Western blotting. (B) Stable expression of FL-B-RafV600E 
and Δ3-B-RafV600E in melan-a cells, and associated pERK levels. (C) 
Proliferation of melan-a cells expressing FL-B-RafV600E and Δ3-B-RafV600E 
cultured in the absence of TPA. Δ3-B-RafV600E cells proliferate faster than FL-
B-RafV600E cells (* P=0.0009, ** P=0.001, *** P=0.0006). (D) Anchorage-
independent growth of melan-a cells expressing FL-RafV600E and Δ3-B-
RafV600E. Δ3-B-RafV600E expressing melan-a cells form significantly more 
colonies in soft agar. The mean and standard deviation of one representative 
experiment done in triplicate is shown in (C) and (D). 
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Figure 4: C-Raf levels in melanoma cell lines modulate B-RafV600E signaling 
and proliferation. (A) B-RafV600E mutant human melanoma cell lines display a 
reduced C-Raf:B-Raf ratio. Evaluation of C-Raf and B-Raf protein levels in 
early stage- and metastases-derived B-RafV600E mutant as well as Nras 
mutant melanoma cells (upper panel). Quantification of expression levels and 
C-Raf:B-Raf ratio is shown in lower panel. C-Raf levels are reduced relative to 
B-Raf in B-RafV600E mutant melanoma cell lines and slightly increased in Nras 
mutant melanoma cells. (B) C-Raf depletion increases ERK activation in B-
RafV600E mutant melanoma cells. Western blot displaying knock-down 
efficiency of C-Raf and accompanying increase of pERK levels is shown. (C) 
C-Raf depletion increases proliferation of B-RafV600E mutant melanoma cells. 
Cells were labelled with BrdU for 6 hours and proliferating cells detected with 
an anti-BrdU antibody. (D) Ectopic expression of myc-C-Raf in WM793 
melanoma cells diminished pERK levels. (E) WM793 cells transfected in (D) 
demonstrated decreased proliferation following C-Raf transfection. The mean 
and standard deviation of one representative experiment done in triplicate is 
shown in (C) and (E, ** P=0.0014, *** P=0.0003). 
 
Figure 5: Oncogenic Ras promotes association of C-Raf and B-RafV600E and 
inhibition of MAPK signaling. (A) HrasG12V activates endogenous C-Raf and 
induces complex formation with endogenous B-Raf in NIH3T3 fibroblasts. 
Western blot shows HrasG12V-induced C-RafS338 phosphorylation, B-Raf–C-
Raf association and MAPK activation in NIH3T3 fibroblasts. (B) HrasG12V 
antagonizes ERK activation in co-transfected HA-B-RafV600E NIH3T3 
fibroblasts. Western blots display HrasG12V-induced HA-B-RafV600E–C-Raf 
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association and decreased pERK levels in B-RafV600E expressing NIH3T3 
fibroblasts. (C) Decreased proliferation of HA-B-RafV600E; HrasG12V co-
expressing fibroblasts depicted in (B). Cells were labelled with BrdU and 
proliferating cells were detected using an anti-BrdU antibody. (D) NrasG12D 
induces B-Raf–C-Raf complex formation and decreases pERK in B-RafV600E 
mutant WM793 melanoma cells. (E) Expression of NrasG12D reduces 
proliferation of WM793 melanoma cells (* P=0.025, ** P=0.0009). The mean 
and standard deviation of one representative experiment done in triplicate is 
shown in (C) and (D). 
 
Figure 6: Sorafenib stabilizes Raf complexes. (A, B) Treatment of HEK293T 
cells expressing ectopic B-RafV600E and C-Raf with Sorafenib increases B-
RafV600E–C-Raf complex formation. Western blot of co-immunoprecipitated C-
Raf and input proteins (A) and quantification of relative amounts of pERK and 
B-RafV600E-bound C-Raf (B) are shown. (C, D) Full length or alternatively 
spliced B-RafV600E were co-expressed with C-Raf in HEK293T cells and 
incubated with increasing concentrations of Sorafenib. (C) Comparison of 
Sorafenib-induced binding of C-Raf to FL-B-RafV600E or Δ3-B-RafV600E. Amount 
of immunoprecipitated C-Raf was normalized to C-Raf bound to FL-B-RafV600E 
in untreated cells. (D) Inhibition of ERK activation by Sorafenib. pERK levels 
were normalized to untreated cells expressing FL-B-RafV600E but no ectopic C-
Raf. (E) Sorafenib enhances B-RafV600E–B-RafV600E association. HEK293T 
cells expressing flag-B-RafV600E and HA-B-RafV600E were treated with 
increasing concentrations of Sorafenib followed by assessment of HA-B-
RafV600E binding to flag-B-RafV600E and activation of ERK. (F) Model of 
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suppression of B-RafV600E signaling by C-Raf. (I) In normal cells, Ras 
stimulates MAPK singaling through activation of both B-Raf and C-Raf. (II) In 
B-RafV600E mutant cells, C-Raf forms complexes with B-RafV600E leading to 
reduced signaling. Complex formation can be promoted by oncogenic Ras-
induced C-Raf activation or Sorafenib.  
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Supplemental Information 
 
Reduced C-Raf affinity of alternatively spliced Δ3-B-Raf 
To address whether suppression of B-RafV600E-mediated MAPK activation 
impaired cell transformation, we employed an alternatively spliced isoform of 
B-Raf, termed Δ3-B-Raf. Δ3-B-Raf is formed through ‘intra-exonal’ splicing, 
leading to a protein lacking 33 amino acids within exon 3 (Suppl. Fig. 1A). Δ3-
B-Raf is ubiquitously expressed in mice, independent of background strain 
and gender (Suppl. Fig. 1B); however, Δ3-B-Raf is not expressed in humans 
likely due to the lack of a splice donor consensus sequence (Suppl. Fig. 1C 
and data not shown). Δ3-B-Raf bound itself as well as full length B-Raf (FL-B-
Raf) with similar efficiency (Suppl. Fig. 2A). Moreover, binding of Δ3-B-Raf to 
Ras, MEK, and 14-3-3 proteins was comparable to FL-B-Raf (data not 
shown). Furthermore, both basal and HrasG12V-induced kinase activities of Δ3-
B-Raf and FL-B-Raf were comparable (Suppl. Fig. 2B). When stably 
expressed in NIH3T3 cells, FL-B-Raf induced slightly higher pERK levels than 
Δ3-B-Raf (Suppl. Fig. 2C), and resulted in a slight but significant increase in 
cell proliferation (Suppl. Fig. 2D). The most striking difference between Δ3-B-
Raf and FL-B-Raf regarded the association with C-Raf. We transiently 
expressed Δ3-B-Raf and FL-B-Raf in HEK293T cells together with HrasG12V to 
induce MAPK signaling. HrasG12V expression led to B-Raf–C-Raf association 
and activation of ERK (Suppl. Fig. 3A and Weber et al., 2001). Interestingly, 
Δ3-B-Raf–C-Raf complex formation was reduced by approximately 45% 
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(Suppl. Fig. 3A and 3B), and correlated with less efficient phosphorylation of 
ERK (Suppl. Fig. 3A). 
 
Splicing occurs in the regulatory, N-terminal part of B-Raf by utilization of 
alternative splice donor and acceptor sites within exon 3, removing a serine-
rich peptide (SRP) from full length B-Raf. Intra-exonic splicing is a rare 
alternative splicing event, which has also been observed for human 
thrombopoietin and fibronectin genes (Chang et al., 1995; Sasaki et al., 1999; 
Vibe-Pedersen et al., 1986). Alternative splicing of ectopically introduced B-
Raf cDNA did not occur, implying that the 99 nucleotides are recognized as 
an intron only in the presence of constitutive introns, similar to the 
thrombopoietin gene (Romano et al., 2001). It has been suggested by 
Romano et al. that the assembly of the splicing machinery on constitutive 
introns is required for intra-exonic splicing to occur. Alternative splicing has 
been observed for B-Raf exons 10 and 8b, which alters the kinase activity of 
the different isoforms (Barnier et al., 1995; Papin et al., 1998). These splice 
forms locate to the hinge region between conserved regions 2 and 3 (CR2 
and CR3) and are therefore likely to modify the conformation of active B-Raf. 
Alternative splicing of the N-terminal regulatory region had no effect on kinase 
activity (Suppl. Fig. 2B). Moreover, binding of B-Raf to Ras was not disrupted 
despite the proximity of the SRP to the Ras binding domain (data not shown). 
Expression of alternatively spliced Δ3-B-RafV600E cDNAs with lower affinity for 
C-Raf in fibroblasts and melanocytes led to increased MAPK activation and 
cell transformation, supporting the finding that B-RafV600E suppression by C-
Raf is dependent on B-Raf–C-Raf interaction. 
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Supplementary Figures  
 
Supplementary Figure 1: Expression of Δ3-B-Raf. (A) Schematic outline 
illustrating alternative splicing of exon 3 of murine B-Raf. (B) Reverse 
Transcriptase PCR analysis of full length and Δ3-B-Raf expression in mouse 
tissues from C57Bl/6 and 129/SvJae mice using intron-spanning primers in 
exons 2 and 4. The upper band represents full length B-Raf, whereas the 
lower band represents Δ3-B-Raf. (C) Reverse Transcriptase PCR analysis of 
full length and Δ3-B-Raf expression in human tissues. br, brain; he, heart; li, 
liver; lu, lung; ki, kidney; sp, spleen; st, stomach; in, intestines; pa, pancreas; 
th, thymus; mu, muscle; sk, skin; le, leukocytes. 
 
Supplementary Figure 2: Effects of alternative splicing. (A) Western blot 
showing HrasG12V-induced formation of Δ3-B-Raf and FL-B-Raf complexes in 
HEK293T cells. White arrowhead denotes FL-B-Raf, black arrowhead 
denotes Δ3-B-Raf, and asterisk denotes background band. (B) Basal and 
HrasG12V-induced B-Raf kinase activity of FL-B-Raf and Δ3-B-Raf in HEK293T 
cells. (C) Western blot displaying phosphorylation of ERK in NIH3T3 
fibroblasts stably expressing FL-B-Raf and Δ3-B-Raf. (D) Proliferation curve of 
NIH3T3 fibroblasts stably expressing FL-B-Raf and Δ3-B-Raf. The mean and 
standard deviation of one representative experiment done in triplicate is 
shown in (B) and (D). 
 
Supplementary Figure 3: Alternative splicing impairs B-Raf–C-Raf complex 
formation and MAPK activation. (A) Western blot showing co-
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immunoprecipitation of C-Raf with FL-B-Raf and Δ3-B-Raf in response to 
HrasG12V activation as well as phosphorylation of ERK in total lysates. (B) 
Quantification of HrasG12V-promoted FL-B-Raf–C-Raf and Δ3-B-Raf–C-Raf 
complexes. 
 
Supplementary Figure 4: Reduced interaction with C-Raf impairs 
transformation by Δ3-B-RafG466V. (A) HrasG12V-induced association of C-Raf 
with FL-B-RafG466V and Δ3-B-RafG466V in HEK293T cells. Immunoprecipitated 
amounts of C-Raf as well as levels of pERK, B-Raf, C-Raf, and HrasG12V in 
the lysates were determined by Western blotting. (B) Stable expression of FL-
B-RafG466V and Δ3-B-RafG466V in NIH3T3 fibroblasts, and associated pERK 
levels were assessed by Western blotting. (C) Proliferation curves of NIH3T3 
fibroblasts expressing FL-B-RafG466V and Δ3-B-RafG466V. FL-B-RafG466V cells 
proliferate faster than Δ3-B-RafG466V cells (* P=0.022, ** P=0.007). (D) 
Anchorage-independent growth of NIH3T3 fibroblasts expressing FL-B-
RafG466V and Δ3-B-RafG466V. FL-B-RafG466V expressing cells form 
approximately 2.5 fold more colonies in soft agar. The mean and standard 
deviation of one representative experiment done in triplicate is shown in (C, * 
P<0.05, ** P<0.01) and (D). 
 
Supplementary Figure 5: Expression of Raf proteins in human melanoma cell 
lines. (A) Western blot displaying expression of C-Raf and B-Raf in human 
melanocyte cell lines NHEM and Fom99-1. (B, C) Estimation of the number of 
B-Raf and C-Raf molecules in a panel of melanoma cell lines. Recombinant 
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B-Raf and C-Raf were run on the same Western blot as reference standards. 
(D) Expression of A-Raf in melanoma cell lines.  
 
Supplementary Figure 6: HrasG12V antagonizes B-RafV600E. (A) HrasG12V 
inhibits ERK activation in B-RafV600E mutant cells. Western blot displaying 
HrasG12V-induced B-RafV600E–C-Raf complex formation and decreased pERK 
levels in WM793 melanoma cells. (B) Decreased proliferation of WM793 
melanoma cells in response to HrasG12V expression. Cells were labelled with 
BrdU and proliferating cells were detected using an anti-BrdU antibody. The 
mean and standard deviation of one representative experiment done in 
triplicate is shown in (B). 
 
Supplementary Figure 7: Response to Sorafenib in melanoma cell lines. 
When treated with increasing doses of Sorafenib, B-RafV600E expressing cell 
lines A375P and WM164 display increased B-Raf–C-Raf complex formation 
as well as increased pERK levels at low doses of Sorafenib and decreased 
pERK at the highest dose of Sorafenib. Mouse embryonic fibroblasts 
expressing endogenous B-RafV619E showed similar kinetics of C-Raf binding 
and pERK level changes in response to Sorafenib. In Nras mutant SKMel2 
cells, pERK levels were not increased at low doses of Sorafenib but B-Raf–C-
Raf complexes were induced. 
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5.1.1 Additional data not included in the manuscript 
Given the high content of putative phospho-residues (15 Serines and two 
Threonines) within the SRP, phosphorylation of the SRP could contribute to 
B-Raf–C-Raf complex formation. Thus, whether post-translational modification 
of the Serine-rich peptide (SRP) deleted in Δ3-B-Raf could regulate B-Raf–C-
Raf heterodimerization was assessed. When flag-tagged B-Raf isoforms were 
separated on 3-7% gradient gels, a slower migrating band in FL-B-Raf 
samples was observed in response to H-RasG12V (Fig. 5.1.1A), suggesting H-
RasG12V-mediated post-translational modification of B-Raf. Importantly, the 
slower migrating band was not observed when cells were co-transfected with 
Δ3-B-Raf and H-RasG12V (Fig. 5.1.1A). Moreover, no slower migrating FL-B-
Raf band was detected after incubation of protein lysates with calf intestinal 
phosphatase, indicating that full length B-Raf is subjected to post-translational 
phosphorylation in response to H-RasG12V (Fig. 5.1.1B). It was determined 
whether H-RasG12V-mediated B-Raf phosphorylation is regulated by a 
feedback loop involving the MAPK pathway. Cells co-expressing FL-B-Raf 
and H-RasG12V were treated with the MEK inhibitor U0126 and assayed for the 
appearance of the slower migrating, phosphorylated B-Raf band by Western 
blot. No alteration of B-Raf phosphorylation in response to MEK inhibition was 
observed (Fig. 5.1.1C), suggesting that feedback-regulation does not play a 
role in B-Raf phosphorylation. To assess whether SRP phosphorylation 
contributes to regulation of B-Raf–C-Raf dimerization, four phospho-mutants 
of B-Raf were generated in which the following amino acids of the SRP were 
mutated to Alanines: PM1, S108-S110-S111-S112-S114; PM2, T117-T119-S120-S121; 
PM3, S122-S123-S124-S125; PM4, S127-S131-S132-S134 (Fig. 5.1.1D, lower panel). 
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No slower migrating, phosphorylated B-Raf was observed when phospho-
mutants PM1, PM2, and PM3 were co-expressed with H-RasG12V (Fig. 5.1.1D, 
upper panel). In contrast, PM4 was still phosphorylated in response to H-
RasG12V, albeit at lower levels (Fig. 5.1.1D, upper panel), indicating that 
Serines 127, 131, 132 and 134 are not subjected to H-RasG12V-mediated 
phosphorylation. To determine the functional significance of SRP 
phosphorylation, the effect of B-Raf phospho-mutants on MAPK pathway 
activation was examined. Interestingly, pERK levels in phospho-mutant 
expressing cells were similar to wildtype, full length B-Raf (Fig. 5.1.1E). 
Accordingly, B-Raf phospho-mutants associated with C-Raf as efficiently as 
wildtype B-Raf (Fig. 5.1.1E), suggesting that B-Raf–C-Raf dimerization is not 
regulated by phosphorylation within the SRP. 
 
 
Figure 5.1.1: Phosphorylation of SRP (A) Western blot showing H-RasG12V-
induced migratory shift of FL-B-Raf but not Δ3-B-Raf. (B) The migratory shift 
is due to phosphorylation. Protein lysates were incubated with calf intestinal 
phosphatase (CIP) and subjected to Western blot analysis using anti-flag 
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antibodies. (C) FL-B-Raf phosphorylation is not regulated by a feedback loop. 
HEK293T cells were incubated with the MEK inhibitor U0126 or DMSO for 24 
hours, followed by Western analysis. (D) Phospho-mutants of FL-B-Raf were 
co-expressed with H-RasG12V in HEK293T cells and analyzed by Western 
blotting. The FL-B-Raf migratory shift was abolished in phospho-mutants 1, 2 
and 3 (upper panel). Schematic representation of B-Raf phospho-mutants 
(lower panel). (E) C-Raf co-immunoprecipitation from cells expressing either 
FL-B-Raf or phospho-mutant isoforms of B-Raf in the presence of H-RasG12V. 
B-Raf was immunoprecipitated with anti-flag antibodies and bound C-Raf 
detected with anti-C-Raf antibodies. 5% of input was used to detect pERK, 
flag-tagged B-Raf and Ras, as well as C-Raf as loading control. 
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5. Results and Discussion 
 
 
 
 
 
 
5.2 Generation of a conditional and reversible oncogenic 
B-Raf mutant mouse model (unpublished data) 
 101
5.2.1 The rationale and strategy for generating a LSL-B-RafV619E mouse 
B-Raf mutations occur frequently in human cancer and are also found at a 
high percentage in benign hyperplasias such as nevi (Brose et al., 2002; 
Davies et al., 2002; Pollock et al., 2003; Pollock and Meltzer, 2002). Most 
notably, B-Raf mutations are present in 60-70% of melanomas. To study the 
biology and oncogenic potential of B-Raf mutations in vivo, a mouse model of 
oncogenic B-Raf was generated. Historically, oncogenes have been 
ectopically expressed in mice as transgenes using strong promoters. The 
expression levels of such transgenes depend not only on the promoter used, 
but are also influenced by the integration site in the genome, the number of 
integrated copies and methylation of the promoter. These factors all contribute 
to abnormal regulation of transgene expression, which typically results in non-
physiological expression levels. Importantly, different expression levels of 
oncogenes have profoundly varying biological outputs. Ectopic expression of 
oncogenic Ras in primary mouse embryonic fibroblasts results in a premature 
growth arrest termed oncogene-induced senescence (Serrano et al., 1997). In 
contrast, expression of oncogenic K-Ras from its endogenous promoter at 
physiological levels increases proliferation and results in immortalization of 
primary mouse embryonic fibroblasts (Tuveson et al., 2004). Moreover, an 
elegant study by Chodosh and colleagues showed that high levels of 
oncogenic H-RasG12V in the mammary epithelium induce senescence, while 
low levels of expression promote proliferation (Sarkisian et al., 2007). 
Similarly, endogenous expression of oncogenic B-Raf results in 
immortalization of MEFs (Mercer et al., 2005), while overexpression in human 
diploid fibroblasts induces senescence (Kuilman et al., 2008). Whether 
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oncogene-induced senescence as caused by overexpression of oncogenic 
Ras in primary cell culture exists as a potent barrier to tumor progression in 
vivo is currently under debate. In addition, high expression levels of myc result 
in apoptosis of pancreatic β-cells; however, low levels of myc have the 
opposite effect and induce proliferation of such cells (Murphy et al., 2008). 
These data emphasize the importance of physiological expression of 
oncogenes to draw biologically relevant conclusions. Thus, the oncogenic B-
Raf allele was designed to be expressed from its endogenous promoter.  
 
In human cancer, over 30 B-Raf missense mutations have been identified. 
The vast majority of cancer cases harbor a Valine-for-Glutamic acid 
substitution at residue 600, which renders B-Raf constitutively active. This 
Valine residue in humans corresponds to Valine 619 in mice. Given its 
predominance in cancer, the oncogenic B-Raf allele was designed to carry the 
V619E mutation. 
 
Global expression of oncogenes could be detrimental to mouse development. 
Indeed, widespread expression of K-RasG12D in LSL-K-RasG12D; CMV-Cre 
mice leads to embryonic lethality (Tuveson et al., 2004). Therefore, oncogenic 
B-RafV619E was designed to be conditionally expressed in the cell type of 
choice. The previously constructed endogenous oncogenic LSL-K-RasG12D 
allele employs a transcriptional and translational STOP cassette. This STOP 
cassette contains a puromycin resistance selection cassette, four SV40 poly-
adenylation signals as well as a strong Kozak sequence followed by a stop 
codon. Additionally, the STOP cassette is flanked by loxP sites. LoxP sites 
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are recognized by Cre recombinase, which deletes the intervening sequence. 
This loxP-STOP-loxP (LSL) cassette can be placed between the promoter 
and the coding sequence of a gene to prevent transcription of the gene. Cre-
mediated excision of the LSL will result in expression of the gene only in cells 
that express Cre recombinase. The LSL cassette was placed in the 5’ region 
of the B-Raf gene to prevent global expression of oncogenic B-RafV619E. By 
crossing LSL-B-RafV619E mice to mouse strains expressing Cre recombinase 
under the control of tissue specific promoters, expression of B-RafV619E can be 
directed to certain cell types.  
 
Whether continuous expression of ‘druggable’ oncogenes is required for 
tumor maintenance is of crucial importance for drug development efforts. If an 
oncogene was no longer required for the survival and tumorigenicity of cancer 
cells, then pharmacological inhibition of this oncogene in an established tumor 
would be futile. The issue of oncogene addiction has been addressed using 
mouse models: withdrawal of oncogenic Ras or myc resulted in tumor 
regression (Chin et al., 1999; Fisher et al., 2001; Jain et al., 2002; Pelengaris 
et al., 2002). To assess whether continuous expression is required for tumor 
maintenance, FRT sites were introduced into the oncogenic B-RafV619E allele 
to additionally create a conditional knock-out of B-RafV619E. FRT sites are 
34bp DNA stretches similar to loxP sites; however, they are recognized by a 
different enzyme, Flp recombinase. Using this approach, expression of 
oncogenic B-RafV619E is restricted to cells expressing Cre recombinase. Once 
neoplasms have developed, Flp recombinase expression can be induced in 
tumor cells resulting in genetic depletion of B-RafV619E and tumor maintenance 
 104
in the absence of the initiating oncogene can be examined. This strategy is 
outlined in Figure 5.2.1.  
 
                  
 
Figure 5.2.1: Conditional and reversible activation of oncogenic B-Raf. Only 
wildtype B-Raf is expressed in B-RafLSL-V619E/WT mice. Upon Cre-mediated 
deletion of the LSL cassette B-RafV619E is expressed from the endogenous 
promoter at physiological levels. B-RafV619E can be conditionally deleted by 
induction of Flp expression and activity. 
 
5.2.2 Design of the LSL-B-RafV619E allele and targeting strategy 
The murine B-Raf gene may contain an alternative promoter in intron 2 that 
drives expression of a truncated B-Raf protein. In fact, some B-Raf antibodies 
recognize several potential murine B-Raf proteins between 60 and 96kDa. To 
prevent expression of truncated oncogenic B-RafV619E, the LSL had to be 
introduced immediately upstream of exon 3 rather than in between the B-Raf 
promoter and exon 1. Therefore, the LSL cassette was knocked-in into intron 
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2 and the V619E mutation was introduced into exon 15. A schematic outline 
of the LSL-B-RafV619E allele is depicted in Figure 5.2.2. The murine B-Raf 
gene encompasses 18 exons and is 115kb in size. Exon 3 and exon 15 are 
approximately 50kb apart. Therefore, the LSL cassette and the V619E 
mutation could not be constructed into a single targeting vector and they had 
to be targeted independently. First, ES cells were targeted with a targeting 
vector containing the LSL, selected using puromyin and screened for correct 
targeting. The LSL targeting was performed first to prevent expression of 
oncogenic B-Raf in ES cells. Expression of oncogenic B-Raf is, of course, 
undesirable as it could lead to loss of pluripotency and the inability to 
contribute to the germline of chimeric mice. In fact, expression of oncogenic 
K-RasG12D and resulting hyperactivation of the MAPK pathway induced 
differentiation of ES cells (D. Tuveson, unpublished observation). LSL-positive 
clones were then electroporated with a second targeting vector carrying 
mutant exon 15 as well as a FRT-flanked neomycin / HSV Thymidine kinase 
(Neo-TK) selection cassette. Double targeted ES cells were subjected to 
G418 selection and surviving clones were examined for correct integration of 
the Neo-TK cassette as well as for the presence of the mutation in exon 15. 
Finally, double positive ES cell clones were electroporated with a Flp 
recombinase expression vector to transiently express the enzyme and remove 
the Neo-TK cassette. ES cells were grown in ganciclovir to select for cells that 
had removed the Neo-TK cassette and surviving clones were screened for the 
presence of only one FRT site in intron 14. 
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Figure 5.2.2: Schematic outline of the B-RafV619E allele. The LSL cassette was 
introduced into intron 2. Black triangles represent loxP sites, white triangles 
represent FRT sites. Wildtype exon 15 was replaced by mutant exon 15 
(depicted as 15*) coding for the V619E mutation. Black numbered boxes 
represent exons. 
 
5.2.3 Design, cloning and targeting of the LSL-FRT targeting vector 
This targeting vector only needed to contain the LSL cassette immediately 5’ 
of exon 3. The LSL cassette contains a puromycin resistance gene and, thus 
no additional selection cassette was required. All elements of the LSL 
cassette are outlined in Figure 5.2.3. To be able to conditionally delete the B-
RafV619E allele after Cre-mediated activation, a FRT site was inserted between 
the LSL cassette and exon 3. The second FRT site will be part of the second 
targeting vector containing mutant exon 15. 
 
 
 
Figure 5.2.3: The LoxP-STOP-LoxP cassette. The LSL is flanked by loxP sites 
(gray triangles) and contains a puromycin resistance gene (puro), which is 
expressed from the ubiquitously active PGK promoter and transcription of 
puro is terminated by a PGK poly-adenylation signal (all in light green). 
Downstream of the puro cassette is a splice acceptor (SA) followed by a 
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buffer sequence (HIS3, both in yellow). Transcripts driven from upstream 
promoters are spliced into the splice acceptor. These transcripts are then 
terminated by the four SV40 poly-adenylation sites (light blue), thereby 
preventing expression of downstream genomic coding sequences. 
Additionally, the LSL contains a Kozak sequence followed by a stop codon 
(TGA) and a splice donor (SD). Should a transcript escape termination by the 
four SV40 polyAs this sequence serves as a backup ‘trap’ to prevent 
expression of downstream genes. The Kozak sequence has a translational 
start codon (ATG) and serves as a ribosome binding site. Translation is then 
stopped by the stop codon that follows the Kozak sequence. The splice donor 
assures that downstream transcripts are spliced to the Kozak – stop codon 
sequence. 
 
To clone the homology arms, a C57Bl/6 BAC (RP24-387G20, BACPAC 
Resources, Children’s Hospital Oakland Research Institute) containing the B-
Raf genomic locus was digested with BamHI and separated on a 0.8% TAE 
agarose gel. Due to the numerous fragments resulting from this digest, the 
DNA ran as a smear. 6-10kb DNA fragments were excised from the gel and 
cloned into FK12-pBS. FK12-pBS is a version of pBluescript where the XhoI 
site in the multiple cloning site of pBluescript was destroyed by cutting with 
XhoI, fill-in of the overhangs using Klenow polymerase followed by blunt end 
ligation. Clones (termed BAC3-FK12-pBS) containing the desired 8.4kb 
fragment, which includes an intronic XhoI site upstream of B-Raf exon 3 were 
identified by colony lift. BAC3-FK12-pBS was end-sequenced using T3 and 
T7 primers and the exon 3 was sequenced to confirm correct cloning. A KpnI-
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Xho-Sal-FRT-Xho-NotI polylinker was cloned into pBluescript using KpnI and 
NotI to generate FK20-pBS. The LSL cassette was then cloned into the SalI 
site of FK20-pBS. Subsequently, the LSL-FRT fragment was cloned into 
BAC3-FK12-pBS with XhoI to generate the LSL-FRT targeting vector. The 
lack of unwanted nucleotide changes in the FRT site, exon 3 and intron-exon 
boundaries was confirmed by sequencing. 
 
E14J ES cells were targeted with 50ug of NotI linearized LSL-FRT targeting 
vector (Figure 5.2.4) and selected in puromycin for one week. 96 clones were 
picked, expanded and screened for the presence of the LSL cassette by long 
range PCR and Southern blotting. 58 clones were positively targeted and two 
clones were further expanded for subsequent targeting of exon 15. 
 
 
 
Figure 5.2.4: Targeting of the LSL cassette (A) LSL-FRT targeting strategy. 
Black triangles, loxP sites; white triangle, FRT site; black box, exon 3. 
Positions of restriction sites used to isolate the homology arms (BamHI) and 
for Southern blotting (NdeI) are shown. Thin white bar labeled “5’ ” represents 
the location of the Southern blot probe used and the size of the Southern blot 
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fragments of the wildtype and targeted allele are depicted below the alleles. 
(B) Southern blot of a wildtype and a targeted ES cell clone. 
 
5.2.4 Design, cloning and targeting of the V619E-Neo-TK targeting vector 
This targeting vector was designed to have two elements: the mutation in 
exon 15 and a Neo-TK selection cassette flanked by FRT sites for 
positive/negative selection. In order to get integration into the genome of both 
the selection cassette and the mutated exon, these elements should be as 
close to each other as possible. The closest suitable and unique restriction 
site to clone the selection cassette was a BamHI site approximately 1350bp 
upstream of exon 15. The FRT site left behind after removal of the NeoTK 
cassette in ES cells serves as the second FRT site to create the conditional 
B-RafV619E knock-out allele. 
 
A 9.8kb fragment containing exons 14, 15, and 16 from a C57Bl/6 BAC 
(RP24-387G20, BACPAC Resources, Children’s Hospital Oakland Research 
Institute) containing the B-Raf genomic locus served as homology arms. The 
fragment was isolated with SalI and XbaI and cloned into pBluescript to 
generate BAC15-pBS in a fashion similar to the LSL-FRT targeting vector’s 
homology arms. This plasmid was end-sequenced using T3 and T7 primers 
and the exons 14, 15, and 16 were sequenced to confirm correct cloning. 
Next, a BamHI-AvrII fragment containing B-Raf exon 15 was sub-cloned into 
pBluescript (BamHI-SpeI), mutated using the site directed mutagenesis kit 
(Stratagene), and, using BamHI and XbaI, cloned into BamHI-AvrII of BAC15-
pBS. Finally, a FRT-Neo-TK-FRT selection cassette (E. Brown, AFCRI) was 
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introduced into the BamHI site to generate the V619E-Neo-TK targeting 
vector. The lack of unwanted nucleotide changes in the FRT sites, exons 14-
16 and intron-exon boundaries was confirmed by sequencing. 
 
LSL-FRT clones #12 and #15 were targeted with 50ug of NotI linearized 
V619E-NeoTK targeting vector (Figure 5.2.5A) and selected in neomycin for 
one week. 48 clones were picked for each LSL-FRT clone, expanded and 
screened for the presence of the Neo-TK cassette by long range PCR and 
Southern blotting (Figure 5.2.5B). A total of 41 clones were positively targeted 
and ten clones were further expanded for sequencing of exon 15. Seven of 
these clones carried the mutation in exon 15 (Figure 5.2.5C). 
 
Since transgenic expression of HSV Thymidine kinase was associated with 
male infertility in mice (Braun et al., 1990), the Neo-TK selection cassette was 
removed in 3 LSL-FRT / V619E-Neo-TK double positive ES cell clones. This 
was achieved by electroporation of a Flp recombinase expression vector and 
selection of cells in ganciclovir. Twelve clones were picked for each of the 
three LSL-FRT / V619E-Neo-TK double positive ES cell clones and screened 
for the presence of only one FRT site in intron 14. Approximately 50% of 
clones were positive for the ‘1-FRT’ PCR reaction (Figure 5.2.5D). Negative 
clones were tested by Southern blot for recombination between the 5’ FRT 
site that was introduced into intron 2 with the LSL-FRT targeting vector and 
the 3’ FRT site of the FRT-Neo-TK-FRT cassette in intron 14. This 
recombination reaction confirmed that both the LSL and the V619E mutation 
were indeed targeted to the same chromosome (Figure 5.2.5E). 
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Figure 5.2.5: Targeting of the V619E mutation (A) LSL-FRT targeting strategy. 
White triangles, FRT sites; numbered black boxes show exons. Positions of 
restriction sites used to isolate the homology arms (SalI and XbaI) and for 
Southern blotting (NcoI) are shown. Thin white bar labeled “5’ ” represents the 
location of the Southern blot probe used and the size of the Southern blot 
fragments of the wildtype and targeted allele are depicted below the alleles. 
(B) Southern blot of a wildtype and a targeted ES cell clone. (C) Sequencing 
of a double positive LSL-FRT / V619E-NeoTK clone. Note that the wildtype 
(green, A) and mutant exons (red, T) are present. (D) PCR of individual Flp-
electroporated LSL-FRT / V619E-NeoTK clones from parental clone #9. The 
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lower band represents wildtype intron 14, the upper band represents intron 14 
containing one FRT site after removal of the Neo-TK cassette. (E) Southern 
blot using EcoRV to test individual Flp-electroporated LSL-FRT / V619E-
NeoTK clones from parental clone #27 for targeting in cis (see text for 
description). Subclone 27-4 has exons 3-14 deleted (ΔB-Raf), indicating that 
the parental clone #27 was targeted in cis with the LSL cassette and the 
V619E mutation. 
 
5.2.5 LSL-B-RafV619E MEFs and mice 
Two clones were expanded and injected into blastocysts by the CRI 
transgenic core. High contribution chimeras were crossed to C57Bl/6 mice 
and both clones transmitted the mutant B-Raf allele through the germline. To 
test the functionality of the allele, mouse embryonic fibroblasts (MEFs) were 
isolated from LSL-B-RafV619E embryos. MEFs were infected with Ad-Cre to 
remove the LSL cassette and induce B-RafV619E expression. Upon B-RafV619E 
expression, MEFs expressed higher levels of pERK compared to Ad-Mock 
infected cells and were able to form foci (Figure 5.2.6A, B), similar to 
oncogenic B-Raf mutant MEFs generated by Dr. R. Marais’ and Dr. C. 
Pritchard’s groups (Mercer et al., 2005). B-RafV619E MEFs changed their 
morphology and looked similar to MEFs expressing endogenous K-RasG12D 
(Figure 5.2.6D and Tuveson et al., 2004). Importantly, the transformed 
morphology of B-RafV619E-expressing cells was reversed upon infection with 
an Ad-Flp virus (Figure 5.2.6D). Recombination of the LSL cassette upon Ad-
Cre infection and conditional knock-out of B-RafV619E was confirmed by PCR 
analysis (Figure 5.2.6E). Furthermore, while expression of B-RafV619E 
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prevents the senescence of MEFs, senescence is induced by subsequent 
infection with Ad-Flp (Figure 5.2.6F), suggesting that deletion of the 
oncogenic B-Raf allele returns MEFs to an untransformed state. Together, 
these data indicate that activation and inactivation of endogenous oncogenic 
B-RafV619E was successful in vitro. To test the LSL-B-RafV619E allele in vivo, 
mice were crossed to the melanocyte-specific, inducible TyrCreERt2 strain 
(Bosenberg et al., 2006), to activate oncogenic B-Raf in melanocytes. LSL-B-
RafV619E; TyrCreERt2 mice were treated with 3 x 2mg Tamoxifen at 4 weeks 
after birth and aged to assess melanocytic hyperplasia development. In two 
similar mouse models, this approach led to hyper-pigmentation of the skin due 
to melanocyte hyper-proliferation within a few weeks (Dankort et al., 2009; 
Dhomen et al., 2009). In one model, melanocytic hyperplasias progressed to 
melanoma (Dhomen et al., 2009). In Tamoxifen-treated LSL-B-RafV619E, 
TyrCreERt2 mice, hyper-pigmentation of the tail skin (Figure 5.2.6C) was 
observed after 4-6 weeks. Thus, Cre-mediated activation of B-RafV619E results 
in skin hyper-pigmentation, verifying that this targeting strategy induces a 
similar phenotype as two alternative B-Raf mouse models of melanoma 
(Dankort et al., 2009; Dhomen et al., 2009). Tamoxifen-treated LSL-B-
RafV619E; TyrCreERt2 mice are currently being aged to determine whether 
hyperplasias progress to melanoma without genetically-engineered, 
concomitant loss of a tumor suppressor gene such as p16INK4A or PTEN. 
Somatic loss of these tumor suppressor genes commonly occurs in 
melanoma and this has been shown to cooperate with B-RafV600E to 
accelerate melanomagenesis (Dankort et al., 2009; Dhomen et al., 2009). 
Expression of endogenous oncogenic B-Raf has been shown to induce lung 
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tumorigenesis (Dankort et al., 2007), and it is currently being tested, whether 
conditional deletion of oncogenic B-RafV619E in lung neoplasms leads to tumor 
regression. 
   
Figure 5.2.6: Characterization of LSL-B-RafV619E MEFs and mice (A) Western 
blot of Ad-Mock and Ad-Cre infected LSL-B-RafV619E MEFs. Deletion of the 
LSL cassette by Ad-Cre results in twice as much B-Raf expression and 
increased pERK levels. (B) Focus formation of Ad-Mock and Ad-Cre infected 
LSL-B-RafV619E MEFs. (C) B-RafV619E; TyrCreERt2 and TyrCreERt2 littermates 
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were i.p. injected with 3 x 2mg Tamoxifen in corn oil to induce B-RafV619E 
expression in melanocytes. Note hyper-pigmentation of tail skin of B-RafV619E; 
TyrCreERt2 mouse. Pictures were taken 10 weeks post Tamoxifen 
administration. (D) Cell morphology of Ad-Mock, Ad-Cre and Ad-Cre + Ad-Flp 
infected LSL-B-RafV619E MEFs. (E) PCR reaction detecting the 
presence/absence of the LSL (LSL, ΔLSL, respectively) and conditional 
knock-out of B-RafV619E (ΔB-RafV619E) in Ad-Mock, Ad-Cre, and Ad-Cre + Ad-
Flp infected LSL-B-RafV619E MEFs. (F) Senescence-associated β-
Galactosidase staining to detect senescent primary MEFs at passage 9. Cells 
not expressing B-RafV619E (Ad-Mock and Ad-Cre + Ad-Flp) enter senescence, 
while B-RafV619E MEFs are protected from senescence. 
 
5.2.6 Generation of R26-LSL-FlpERt2 mice 
In order to inactivate oncogenic B-RafV619E, the Flp recombinase must be 
present in B-Raf mutant cells. Moreover, Flp has to remain dormant until B-
RafV619E is supposed to be inactivated. Therefore, a mouse models that 
expresses a Flp-ERt2 fusion protein under the control of the rosa26 promoter 
was generated. ERt2 is the mutant ligand binding domain of the human 
estrogen receptor and is bound to heat shock proteins in the cytosol. If the 
ERt2 domain is fused to a recombinase, the recombinase will be inactive until 
ERt2 binds to its ligand, Tamoxifen, which triggers a release from heat shock 
proteins and allows enzymatic activity of the recombinase. The rosa26 
promoter is ubiquitously expressed, making this FlpERt2 allele a useful 
reagent for various cancer models. However, to limit FlpERt2 expression to 
cells that express the oncogene of choice, a LSL cassette was inserted 
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between the rosa26 promoter and the FlpERt2 coding sequence. In addition 
to studying oncogene addiction, this allele is suitable to investigate sequential 
gene targeting such as oncogene activation followed by tumor suppressor 
inactivation in developed tumors. The design and targeting strategy of 
FlpERt2 allele are shown in Figure 5.2.7A.  
 
To generate the FlpERt2 allele, Flp was amplified from pCAGGS-Flpe using 
an upstream primer containing a NheI and a SalI site as well as a viral splice 
acceptor and a downstream primer containing a BamHI site: SA-Flp-up 5’-
gcGCTAGCgtcgacagggcgcagtagtccagggtttccttgatgatgtcatacttatcctgtcccttttttttc
cacagccatggctcccaag-3’ (NheI site is in capital letters, SalI site is in bold, 
SV40 splice acceptor is underlined) and SA-Flp-dwn 5’-
cagcagaggatcctatgcgtc-3’ (BamHI site is underlined). In parallel, ERt2-
SV40pA was amplified from a CreERt2 plasmid (provided by Dr. P. Chambon) 
using an upstream primer containing a BamHI site and a downstream primer 
containing a NheI site: ERt2-SV40pA-up 5’-gacgcataggatcctctgctg-3’ (BamHI 
site is underlined) and ERt2-SV40pA-dwn 5’-gcgctagcccagacatgataagatac-3’ 
(NheI site is underlined). The SA-Flp and ERt2-SV40pA PCR products were 
digested with NheI/BamHI and BamHI/NheI and triple ligated into modified 
pBluescript containing a NheI site. Flp was fused to the ERt2 in a similar 
fashion as previously published (Hunter et al., 2005), suggesting that this 
fusion protein is likely to be functional. The SA-Flp-ERt2-SV40pA sequence 
was verified by sequencing followed by cloning into the NheI site of a rosa26 
genomic fragment in pBluescript. Finally, the LSL cassette was inserted into 
the SalI site to generate the R26-LSL-FlpERt2 targeting vector. 
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Figure 5.2.7: Targeting of the LSL-FlpERt2 allele (A) LSL-FlpERt2 targeting 
strategy. NotI and ClaI restriction sites mark the borders of the homology 
arms. EcoRI was used to digest genomic DNA for Southern blotting. Thin 
white bar labeled “5’ ” represents the location of the Southern blot probe used 
and the size of the Southern blot fragments of the wildtype and targeted allele 
are shown below the alleles. (B) Southern blot of a wildtype and two targeted 
ES cell clones. 
 
E14J ES cells were targeted with 50ug of NotI linearized R26-LSL-FlpERt2 
targeting vector, selected in puromycin, 48 clones picked and screened for the 
presence of the LSL-FlpERt2 allele by Southern blotting (Figure 5.2.7B). Two 
positive clones were expanded and injected into blastocysts. High contribution 
chimeras were crossed to C57Bl/6 mice and agouti offspring were genotyped 
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for the LSL-FlpERt2 allele. F1 LSL-FlpERt2 mice were crossed to a Flp-
reporter strain (placental alkaline phosphatases, PLAP, Awatramani et al., 
2001) and MEFs isolated. Double mutant MEFs were infected with Ad-Cre to 
delete the LSL cassette and treated with 10 and 100nM 4-Hydroxytamoxifen 
(4-OHT) for 3 days to induce Flp activity, which drives PLAP expression. 
Staining of MEFs for alkaline phosphatase revealed that only Ad-Cre infected, 
4-OHT treated cells were positive for PLAP (Figure 5.2.8), indicating that the 
LSL-FlpERt2 allele works under these conditions. LSL-FlpERt2 mice were 
then crossed to Ub-CreERt2 (E. Brown, AFCRI) mice and treated with 
Tamoxifen to remove the LSL cassette in the germline and generate FlpERt2 
mice. FlpERt2 mice were crossed to PLAP mice, treated with Tamoxifen and 
are currently being examined for in vivo activity of the FlpERt2 allele. 
 
       
 
Figure 5.2.8: FlpERt2 activity in vitro. Ad-Cre and Ad-Mock infected LSL-
FlpERt2; PLAP MEFs were treated with 10 and 100nM 4-OHT and incubated 
with BM Purple solution containing NBT and BCIP to detect alkaline 
phosphatase activity. Ad-Cre infected cells that were treated with 100nM 4-
OHT showed some alkaline phosphatase positivity. 
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In summary, I have created two genetically engineered mouse strains, which 
are currently being characterized in detail. LSL-B-RafV619E mice displayed no 
overt phenotype indicating that oncogenic B-Raf is not expressed in the 
absence of Cre activity. When crossed to TyrCreERt2 mice and treated with 
Tamoxifen, LSL-B-RafV619E mice showed increased pigmentation of skin, due 
to expansion of the pool of melanocytes. In vitro, MEFs were transformed by 
expression of B-RafV619E, and reversibility of the allele was demonstrated by 
infecting with Ad-Flp. Thus, the LSL-B-RafV619E allele was shown to be 
functional in vivo and in vitro. MEFs derived from R26-LSL-FlpERt2 mice 
harboring a Flp reporter were infected with Ad-Cre and treated with 4-OHT. 
This resulted in PLAP activity, indicating that this allele, too, is functional. 
These alleles will be useful tools to further investigate the role of oncogenic B-
Raf in tumor biology. 
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5. Results and Discussion 
 
 
 
 
 
 
5.3 The role of B-Raf and C-Raf in K-RasG12D-induced 
lung tumorigenesis (unpublished data) 
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5.3.1 Rationale 
Ras is mutated in approximately 30% of human cancers (Bos, 1989). Of the 
three Ras family members, K-Ras is predominantly found mutated and mouse 
models have provided experimental evidence that K-Ras has oncogenic 
properties in the lung, pancreas, hematopoietic system, colon, endometrium, 
and soft tissue (Karreth and Tuveson, 2009). Therapeutic targeting of Ras 
itself has been unsuccessful so far. Targeting Ras effector pathways may 
therefore represent an alternative therapeutic option to treat Ras mutant 
tumors. Thus, the Ras effector pathway(s) required for transmitting the effects 
of oncogenic Ras need to be determined. In the lung, PI3K and Rac have 
been shown to be critical for K-RasG12D-mediated tumorigenesis (Gupta et al., 
2007; Kissil et al., 2007). In human cells, RalA but not RalB is critical for 
oncogenic Ras-induced cell transformation (Lim et al., 2005). Finally, C-Raf is 
essential for tumor formation and maintenance in a squamous cell carcinoma 
model (Ehrenreiter et al., 2009). However, the role of the Raf-MEK-ERK 
pathway downstream of endogenous K-RasG12D in lung tumorigenesis 
remains to be investigated. To this end, B-Raffl/fl; K-RasG12D and C-Raffl/fl; K-
RasG12D compound mutant mice were generated to analyze the importance of 
B-Raf and C-Raf in mediating the oncogenic K-RasG12D effects in the lung. 
 
5.3.2 Lung tumor development 
B-Raffl/fl; K-RasG12D and C-Raffl/fl; K-RasG12D mutant mice and control mice (B-
Raffl/wt; K-RasG12D and C-Raffl/wt; K-RasG12D, respectively as well as K-RasG12D 
mice on the same genetic background as the compound mutant mice) were 
infected with Ad-Cre via intranasal instillation at 4-6 weeks of age. Mice were 
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aged for 6, 9, and 12 weeks, and tumor burden examined. Even though there 
was a trend towards reduced tumor burden in B-Raffl/fl; K-RasG12D mice 
compared to control mice at all investigated time points, it never reached 
statistical significance (Figure 5.3.1). Similarly, C-Raffl/fl; K-RasG12D mice 
showed slightly but not significantly reduced lung tumor burden at 6 and 9 
weeks when compared to control mice. However, at 12 weeks following Ad-
Cre infection, lung tumor burden of C-Raffl/fl; K-RasG12D was significantly 
reduced (Figure 5.3.1). These data suggest that C-Raf may play a more 
important role than B-Raf in K-RasG12D-mediated lung tumorigenesis at these 
early stages. 
          
 
Figure 5.3.1: Lung tumor burden. Tumor burden at 6 weeks (top left), 9 weeks 
(top right), and 12 weeks (bottom left) post Ad-Cre infection. B-Raffl/fl; K-
RasG12D mice display slightly decreased tumor burden compared to B-Raffl/wt; 
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K-RasG12D and K-RasG12D control mice at all three time-points; however, the 
decrease was not statistically significant. Tumor burden of C-Raffl/fl; K-RasG12D 
mice was significantly reduced 12 weeks post Ad-Cre infection when 
compared to control mice, and slightly but not significantly at earlier time-
points. 
 
Next, the number of neoplasms per lung area at 12 weeks was determined. B-
Raffl/fl; K-RasG12D displayed a reduced number of the least abundant type of 
neoplasm, bronchiolar hyperplasias (BH), but no significant reduction of 
adenomatous alveolar hyperplasias (AAH) and adenomas (Figure 5.3.2). In 
contrast, C-Raffl/fl; K-RasG12D mice exhibited a significant reduction in BH, 
AAH, and adenomas (Figure 5.3.2), suggesting that the lower number of 
neoplasms results in reduced lung tumor burden of C-Raffl/fl; K-RasG12D mice. 
These findings suggest that C-Raf may play a role in tumor initiation by K-
RasG12D. 
 
Figure 5.3.2: Number of neoplasms. B-Raffl/fl; K-RasG12D mice develop fewer 
BH than control mice but the number of AAH and adenomas is not reduced 
(left panel). The number of AAH, BH, and adenomas is significantly 
decreased in C-Raffl/fl; K-RasG12D mice (right panel). 
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5.3.3 Survival of B-Raffl/fl; K-RasG12D and C-Raffl/fl; K-RasG12D mice 
B-Raffl/fl; K-RasG12D and C-Raffl/fl; K-RasG12D and appropriate control mice 
were aged to assess survival of these mice. Mice were sacrificed once they 
showed signs of rapid, labored breathing, piloerection, hunched posture, 
inactivity, loss of social behavior with cage mates and loss of a significant 
amount of their body weight (>20%). Interestingly, genetic ablation of both B-
Raf and C-Raf in the context of oncogenic K-RasG12D extended the median 
survival for approximately 50 days (Figure 5.3.3). Thus, while extended 
survival of C-Raffl/fl; K-RasG12D mice is likely due to reduced initiation of 
neoplasms, tumor development in B-Raffl/fl; K-RasG12D mice appears to be 
impaired at later stages, leading to increased survival. 
 
 
Figure 5.3.3: Survival curves. Homozygous deletion of B-Raf in K-RasG12D 
lung cells significantly extends survival compared to B-Raffl/wt; K-RasG12D mice 
(median survival: B-Raffl/fl; K-RasG12D, 249 days vs. B-Raffl/wt; K-RasG12D, 
200.5 days) (left panel). Similarly, C-Raffl/fl; K-RasG12D mice display an 
increase in median survival (268 days) compared to C-Raffl/wt; K-RasG12D mice 
(211 days) (right panel). 
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5.3.4 MAPK activation and proliferation in vivo 
To determine whether increased survival of B-Raffl/fl; K-RasG12D and C-Raffl/fl; 
K-RasG12D mice is due to impaired MAPK activation, lung sections were 
stained for pERK. Unfortunately, pERK levels are not increased in lung 
neoplasms compared to normal alveolar tissue at 6, 9, and 12 weeks post Ad-
Cre infection independent of the genotype (Figure 5.3.4). This is likely due to 
K-RasG12D mediated activation of negative regulators of the MAPK pathway, 
such as Sprouty proteins (Shaw et al., 2007).  
 
 
Figure 5.3.4: pERK staining in lung neoplasms of K-RasG12D mice. No 
immunohistochemical staining was detected at early time-points (K-12wks, K-
RasG12D mouse 12 weeks post Ad-Cre infection), while some neoplasms 
showed pERK positivity at late time-points (K-8mo, K-RasG12D mouse 8 
months post Ad-Cre infection).  
 
Next, proliferation of neoplasms at 12 weeks post Ad-Cre infection was 
assessed by staining lung sections for Ki-67. Proliferation of neoplasms in C-
Raffl/fl; K-RasG12D mice was not significantly different when compared to 
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control mice (Figure 5.3.5). Intriguingly, proliferation of AAH and early grade 
adenomas was reduced in B-Raffl/fl; K-RasG12D mice, demonstrating that 
increased survival of these mice correlates with a slower growth of 
neoplasms. Thus, both B-Raf and C-Raf are important for K-RasG12D-driven 
lung tumorigenesis. 
 
 
 
Figure 5.3.5: Proliferation of early grade neoplasms. Percentage of Ki-67 
positive cells in AAH and adenomas 12 weeks post Ad-Cre infection is shown. 
Homozygous deletion of B-Raf in K-RasG12D expressing neoplastic cells 
impairs proliferation, whereas ablation of C-Raf expression has no effect on 
proliferation. 
 
5.3.5 B-Raffl/fl; K-RasG12D and C-Raffl/fl; K-RasG12D MEFs 
Endogenous expression of oncogenic K-RasG12D partially transforms mouse 
embryonic fibroblasts. K-RasG12D MEFs show increased rates of proliferation, 
loss of contact inhibition and are immortal (Tuveson et al., 2004). Features of 
 127
oncogenic K-Ras activity were examined in B-Raffl/fl; K-RasG12D and C-Raffl/fl; 
K-RasG12D MEFs. First, proliferation was assessed in 10% and 2% fetal calf 
serum. Interestingly, Ad-Cre infected C-Raffl/fl; K-RasG12D MEFs displayed 
increased proliferation compared to Ad-Mock infected control cells similar to 
K-RasG12D cells (Figure 5.3.6A, B). In contrast, K-RasG12D cells lacking B-Raf 
proliferate similar to Ad-Mock infected control cells (Figure 5.3.6A, B), 
indicating that B-Raf but not C-Raf is required for K-RasG12D to promote 
proliferation of MEFs. Next, signaling downstream of Raf was investigated. 
pERK levels are slightly decreased when K-RasG12D-expressing cells are 
grown in 10% FCS (Tuveson et al., 2004). Similar decreases in pERK levels 
were observed in Ad-Cre infected B-Raffl/fl; K-RasG12D MEFs, while C-Raffl/fl; 
K-RasG12D MEFs displayed higher levels of pERK. Interestingly, when grown 
in 2% FCS, pERK levels in Ad-Cre infected K-RasG12D and C-Raffl/fl; K-
RasG12D cells were not significantly different from those of Ad-Mock infected 
cells. In contrast, pERK levels were markedly decreased in Ad-Cre infected B-
Raffl/fl; K-RasG12D MEFs compared to Ad-Mock infected controls when grown 
in 2% FCS (Figure 5.3.7), indicating that K-RasG12D activates the MAPK 
pathway primarily through B-Raf under these conditions. These in vitro data 
corroborate the in vivo finding of reduced proliferation of AAH and adenomas 
in B-Raffl/fl; K-RasG12D mice, which is likely due to impaired MAPK signaling. 
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Figure 5.3.6: Proliferation of MEFs in 10% and 2% serum. (A) Proliferation 
curves of Ad-Mock or Ad-Cre infected K-RasG12D, B-Raffl/fl; K-RasG12D, or C-
Raffl/fl; K-RasG12D MEFs in 10% FCS. (B) Proliferation curves of Ad-Mock or 
Ad-Cre infected K-RasG12D, B-Raffl/fl; K-RasG12D, or C-Raffl/fl; K-RasG12D MEFs 
in 2% FCS. 
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Figure 5.3.7: Western blot analysis in 10% and 2% serum. B-Raf, C-Raf and 
K-Ras blots show appropriate recombination of the respective alleles when 
infected with Ad-Cre. pERK levels are markedly reduced in B-RafΔ/Δ; K-
RasG12D MEFs grown in 2% serum. K, K-RasG12D; BBK, B-Raffl/fl; K-RasG12D; 
CCK, C-Raffl/fl; K-RasG12D; M, Ad-Mock; C, Ad-Cre. 
 
C-Raf has been shown to have anti-apoptotic activity by antagonizing ASK1, 
MST2, ROKα, and BAD (Chen et al., 2001; O'Neill et al., 2004; Piazzolla et 
al., 2005; Wang et al., 1996). Therefore, a potential anti-apoptotic role of C-
Raf in K-RasG12D MEFs was investigated. K-RasG12D, B-Raffl/fl; K-RasG12D and 
C-Raffl/fl; K-RasG12D MEFs infected with Ad-Cre showed no apoptotic 
phenotype; however, K-RasG12D MEFs were less sensitive to induction of 
apoptosis by either TNFα or Staurosporine when compared to Ad-Mock 
infected control cells (Figure 5.3.8). Genetic ablation of B-Raf in K-RasG12D 
cells did not prevent the K-RasG12D-mediated protection from apoptosis. 
Intriguingly, deletion of C-Raf negated the anti-apoptotic effect of K-RasG12D 
(Figure 5.3.8), indicating that K-RasG12D signals through C-Raf to confer 
reduced sensitivity to apoptotic stimuli. Whether the lack of C-Raf in K-
RasG12D lung epithelial cells induces apoptosis remains to be determined. No 
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increased apoptosis was detected in C-Raffl/fl; K-RasG12D neoplasms at 6, 9, 
and 12 weeks post Ad-Cre infection (Figure 5.3.9), indicating that if the lack of 
C-Raf induces apoptosis in K-RasG12D-expressing cells, it occurs immediately 
after induction of oncogenic K-Ras expression. 
 
Figure 5.3.8: Anti-apoptotic effect of K-RasG12D requires C-Raf. Apoptosis was 
induced by treatment with 10ng/ml TNFα or 5nM Staurosporine of Ad-Mock or 
Ad-Cre infected K-RasG12D, B-Raffl/fl; K-RasG12D, or C-Raffl/fl; K-RasG12D MEFs. 
 
 
Figure 5.3.9: Apoptosis in vivo. No apoptosis of neoplastic cells in K-RasG12D, 
B-Raffl/fl; K-RasG12D, or C-Raffl/fl; K-RasG12D mice 12 weeks post Ad-Cre 
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infection. Lungs were immunohistochemically stained for cleaved Caspase 3. 
K, K-RasG12D; BBK, B-Raffl/fl; K-RasG12D; CCK, C-Raffl/fl; K-RasG12D. 
 
5.3.6 Future directions 
I have shown that both B-Raf and C-Raf are important for K-RasG12D-mediated 
lung tumor development. Interestingly, B-Raf and C-Raf play distinct roles: 
while B-Raf regulates MAPK signaling and proliferation, C-Raf is dispensable 
for MEK/ERK activation but rather is critical for survival of K-Ras mutant cells 
in vitro and tumor initiation in vivo. Several experiments will be performed to 
further elucidate the role of B-Raf and C-Raf in K-RasG12D-driven 
tumorigenesis. First, the recombination efficiency of the floxed B-Raf and C-
Raf alleles in K-RasG12D mutant lung tumor cells will be determined. As B-Raf 
and/or C-Raf could be absolutely required for K-RasG12D-mediated lung 
tumorigenesis, the developing lesions could have undergone only 
heterozygous recombination of the floxed alleles. To further determine the 
role of B-Raf in MAPK signaling and cell cycle regulation in response to K-
RasG12D, expression of cell cycle regulators in vitro and in vivo will be 
examined. Furthermore, pERK levels will be analyzed in advanced tumors, 
where they have been shown to be elevated (Jackson et al., 2005). Moreover, 
the activation of anti-apoptotic effectors downstream of C-Raf as well as 
expression of pro-/anti-apoptotic proteins in K-RasG12D mutant MEFs will be 
analyzed to better understand the pro-survival function of C-Raf in such cells. 
Finally, to further investigate the mechanism of reduced tumor initiation in C-
Raffl/fl; K-RasG12D mice, compound mutant mice carrying a Cre reporter were 
generated. Apoptosis and proliferation will be assessed in Cre reporter 
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positive lung epithelial cells to determine the immediate biological response to 
K-RasG12D activation. These additional data will hopefully provide some 
mechanistic insights and will allow publication of this project. 
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6. Conclusions 
 
The goal of this thesis was to genetically and biochemically dissect the 
functions of Raf proteins in tumorigenesis. Given the frequent occurrence of 
B-Raf mutations in melanoma as well as the lack of a tractable mouse model 
of melanoma at the time of commencement of this thesis, the primary 
objective was to create and characterize a conditional LSL-B-RafV619E mutant 
mouse. My design of the transgenic allele included three features: (1) 
endogenous expression of oncogenic B-RafV619E, (2) activation upon Cre 
expression to direct B-RafV619E to the cell type of choice and (3) reversibility of 
B-RafV619E expression by means of a Flp/FRT recombinase system. 
Endogenous expression of B-RafV619E upon Cre expression is required to 
closely mimic the genetic context of the human cancer that is being modeled. 
Deactivation of oncogenic B-RafV619E is the first attempt to genetically abolish 
expression of an endogenously expressed oncogene. Even though genetic 
and pharmacological means of inactivating oncogenic B-Raf are not 
equivalent, this approach will be informative as to whether oncogenic B-Raf 
itself is a suitable therapeutic target in established tumors. The design of the 
LSL-B-RafV619E allele also has two main limitations: (1) ES cells had to be 
targeted three times, which was time and labor intensive and led to reduced 
pluripotency of some ES cell clones due to the stress inflicted by prolonged 
time in culture and multiple targeting. (2) Cells not expressing oncogenic B-
Raf will be heterozygous for B-Raf. Even though B-Raf heterozygosity in mice 
results in no overt phenotype, B-Raf gene dosage could influence the 
response of the microenvironment to tumor formation. 
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Despite several setbacks (e.g. poor targeting efficiency due to short homology 
arms of the targeting vectors and no germline transmission with the first ES 
cell line used), the LSL-B-RafV619E mouse as well as the R26-LSL-FlpERt2 
mouse were created and are currently being characterized in detail. Initial 
analysis of the LSL-B-RafV619E mouse model revealed that expression of 
oncogenic B-Raf induced hyper-pigmentation in a fashion similar to two 
previously published oncogenic B-Raf mouse models (Dankort et al., 2009; 
Dhomen et al., 2009). Therefore, this mouse model is a useful tool to study 
the biology of oncogenic B-Raf in melanoma development and genetically 
assess whether B-Raf is a suitable therapeutic target. Furthermore, when 
combined with loss of melanoma-associated tumor suppressor genes to 
accelerate tumor formation, this mouse model can be utilized to evaluate 
novel therapeutic agents in a preclinical setting. Moreover, this mouse model 
can be employed in a transposon-based forward genetic screen in an effort to 
identify tumor suppressor genes and oncogenes that co-operate with B-
RafV619E in melanoma development. Finally, this mouse model will be useful to 
further investigate the interplay between oncogenic B-Raf and C-Raf in vivo. 
 
Oncogenic B-Raf mutants with impaired kinase activity towards MEK have 
been shown to activate C-Raf, thereby leading to aberrant MAPK signaling. It 
had been known that Raf proteins form heterodimers in a Ras-dependant 
manner (Farrar et al., 1996; Luo et al., 1996; Weber et al., 2001) and that 
different Raf dimers possess varying kinase activities (Rushworth et al., 
2006); however, the notion that Raf proteins affect the activity of each other 
added a new layer of complexity to the regulation of the MAPK pathway. 
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During my PhD I discovered that while the interaction of C-Raf with impaired 
activity B-Raf mutants promoted hyperactivation of the MAPK pathway, C-Raf 
antagonizes B-RafV600E-mediated MAPK signaling. Interestingly, C-Raf inhibits 
B-RafV600E by lowering its kinase activity. These data together with the finding 
that impaired activity mutant B-Raf induces C-Raf kinase activity suggest that 
B-Raf activates C-Raf while C-Raf inhibits B-Raf. Thus, in a B-Raf–C-Raf 
heterodimer, C-Raf might be the MEK-activating component, while B-Raf has 
functions other than activating MEK. My findings contribute to the 
understanding of the regulation of MAPK activation by oncogenic B-Raf and 
could potentially be explored therapeutically by developing drugs that 
specifically stabilize B-RafV600E–C-Raf heterodimers. 
 
As part of the B-RafV600E–C-Raf interaction study, I discovered a previously 
uncharacterized alternative murine B-Raf splice variant. Splicing occurs in the 
regulatory, N-terminal part of B-Raf by utilizing alternative splice donor and 
acceptor sites within exon 3 and leads to deletion of a Serine-rich peptide 
(SRP). Intra-exonic splicing is a rare alternative splicing event, which has also 
been observed for human thrombopoietin and fibronectin genes (Chang et al., 
1995; Sasaki et al., 1999; Vibe-Pedersen et al., 1986). Alternative splicing of 
B-Raf cDNA did not occur, implying that the 99 nucleotides are recognized as 
an intron only in the presence of constitutive introns, similar to the 
thrombopoietin gene (Romano et al., 2001). It has been suggested by 
Romano et al that the assembly of the splicing machinery on constitutive 
introns is required for intra-exonic splicing to occur. Alternative splicing has 
been observed for B-Raf exons 10 and 8b, which alters the kinase activity of 
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the different isoforms (Barnier et al., 1995; Papin et al., 1998). These splice 
forms locate to the hinge region between conserved regions 2 and 3 (CR2 
and CR3) of B-Raf and are therefore likely to modify the conformation of 
active B-Raf as proposed by Papin et al. Alternative splicing of the N-terminal 
regulatory region had no effect on kinase activity. Moreover, binding of B-Raf 
to Ras was not disrupted despite the proximity of the SRP to the Ras binding 
domain (chapter 5.1). Interestingly, the SRP is phosphorylated in response to 
H-RasG12V overexpression. Phosphorylation does not affect MAPK signaling 
or B-Raf–C-Raf heterodimerization, indicating that SRP phosphorylation could 
be important for MAPK-independent functions. However, phosphorylation 
could be an artifact of concomitant B-Raf and H-RasG12V overexpression and 
remains to be further evaluated. 
 
I describe how oncogenic Ras activates C-Raf, thereby promoting association 
with oncogenic B-Raf. In the case of impaired activity mutant B-Raf this 
augments activation of MEK. However, Ras-induced association of C-Raf with 
B-RafV600E antagonizes MAPK signaling. Indeed, oncogenic Ras mutations 
and B-RafV600E mutations are mutually exclusive in human cancer while Ras 
and non-B-RafV600E mutations have been reported to co-occur (Thomas et al., 
2007). Previously, the exclusivity of Ras and B-RafV600E was attributed to 
redundant activation of downstream pathways. However, it appears that 
hyperactivation of the MAPK pathway is antagonized rather than promoted by 
expression of both oncogenes. Co-operation of oncogenes has been well 
established and analyzed in numerous contexts; however, to my knowledge 
this is the first report of oncogene antagonism. 
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Identification of the pathways employed by oncogenic Ras to induce and 
maintain a transformed state of a cell is crucial to therapeutically target Ras 
cancers as targeting Ras itself has been unsuccessful so far. The PI3K and 
Rac pathways in lung cancer (Gupta et al., 2007; Kissil et al., 2007) and C-
Raf–ROKα–myc axis in squamous cell carcinoma (Ehrenreiter et al., 2009) 
have been shown to be important for Ras-driven tumorigenesis. Lung tumors 
in PI3K and K-Ras mutant mice regressed upon combination treatment with 
AKT and MEK inhibitors (Engelman et al., 2008), implicating the MAPK 
pathway in maintenance of K-Ras mutant lung tumors. Which Raf protein is 
employed to activate MEK/ERK in K-RasG12D mutant tumors is unknown. 
Genetic deletion of either B-Raf or C-Raf in K-RasG12D expressing lung 
epithelial cells extended survival of these animals, indicating that both Raf 
proteins are important for tumorigenesis. Interestingly, B-Raf and C-Raf 
appear to serve distinct functions in the context of K-RasG12D. Similar to 
wildtype cells, B-Raf is the major activator of the MAPK pathway in K-RasG12D 
mutant cells and controls proliferation. In contrast, C-Raf is dispensable for 
MAPK activation and control of proliferation but is important for tumor initiation 
in vivo and survival in vitro. The mechanisms of these independent functions 
remain to be further elucidated. Importantly, using this approach B-Raf or C-
Raf was deleted at the same time as expression of oncogenic K-Ras was 
initiated. It therefore needs to be established whether genetic or 
pharmacological inactivation of B-Raf and/or C-Raf (and A-Raf) in an 
established tumor inhibits tumorigenesis. In that case Raf inhibitors alone or in 
combination with drugs targeting other Ras effector pathways could be 
beneficial to cancer patients. 
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Hyperactivation of the MAPK pathway by oncogenic Ras or B-Raf and the 
consequent cell transformation has been firmly established. However, the 
regulation of these signals is complex and only incompletely understood. For 
example, MEFs expressing K-RasG12D display increased levels of cyclins, 
known targets of the MAPK pathway, even though phosphorylation of ERK is 
attenuated (Tuveson et al., 2004). Recent studies have shed some light on 
how interactions of Raf proteins with each other or oncogenic Ras affect 
MAPK signaling and cell transformation. It is becoming increasingly clear that 
regulation of the MAPK pathway in wildtype and oncogenic contexts is more 
complex than anticipated. For instance, B-Raf has been determined to be the 
major activator of the MAPK pathway and is the only Raf protein mutated in 
cancer due to its mode of activation. C-Raf, on the other hand is very rarely 
mutated in cancer. The fact that C-Raf is essential for MAPK hyperactivation 
by impaired activity mutant B-Raf indicates that C-Raf, too, plays pivotal roles 
in cancer development in some contexts. Furthermore, C-Raf is critical in 
Ras-driven lung and skin cancer, suggesting that Ras-mediated activation of 
the MAPK pathway alone is not sufficient to induce and maintain neoplasms. 
The extensive complexity of the MAPK pathway represents ample 
opportunities for identifying suitable therapeutic targets. However, hitting 
these targets may be clinically relevant only in certain scenarios, for instance 
in cancers harboring an impaired activity B-Raf mutation. Therefore, 
determining the B-Raf mutation status in tumors to choose the most 
appropriate therapy will be imperative for personalized cancer treatment. 
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